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“I think that only daring speculation can lead 
us further and not accumulation of facts.” 
 
Albert Einstein 
 
 
“Judah Folkman (who was both a surgeon and 
a basic scientist) once said that the difference 
between surgeons and basic scientists is that 
when someone can’t reproduce the results of a 
basic scientist, the scientist becomes alarmed. 
When someone can’t reproduce the results of a 
surgeon, the surgeon takes it as a compliment to 
their superior skills.” 
 
Brent R. Stockwell: The Quest for the Cure 
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Abstract 
Cerebrovascular diseases continue to challenge us by robbing lives and leaving many 
disabled still in their prime working age. Some cerebrovascular diseases are more 
acute in nature, and some erode the quality of life over a long period of time.  
 
A life-threatening form of acute cerebrovascular disease is brought on by the rupture 
of an intracranial aneurysm (IA). Most IAs are berry-shaped pouches at the forking 
site of cerebral arteries. Since according to autopsy results, 2-5% of the population 
harbours IA, it is a common disease. Most IA go unnoticed during one’s lifetime, 
however, often the first symptom they give is their deadly rupture. Likely, both envi-
ronmental factors and a compound genetic susceptibility, contribute to the risk of 
IA, making it a complex disease. The aim of studies I-III was to test whether in hu-
mans common genetic variants contribute to the susceptibility to IA (I,II), and to 
seek genetic evidence for their pathomechanism (III). In multinational genome-wide 
association studies (I,II) we identified 5 loci with strong statistical evidence of asso-
ciation with IA, and a further 14 loci with suggestive evidence. Further, we found 
that suggestive IA risk locus at 5q26 is strongly associated with high systolic blood 
pressure in over 210 000 individuals of European descent, highlighting the connec-
tion between hypertension and IA (III). 
 
To gain further insight into cerebral vasculopathies and to facilitate the develop-
ment of novel therapies, in study (IV) we turned our attention to vascular growth 
factor induced angiogenesis in a model organism. We tested by viral gene transfer 
the known vascular growth factors in the murine central nervous system and charac-
terised extensively the angiogenesis upon treatment. The aim of the study was to 
identify the best candidate vascular growth factor(s) for therapeutic brain angiogene-
sis. We identified placenta growth factor as the most safe and efficient candidate for 
therapeutic revascularisation of the central nervous system. We envision a placenta 
growth factor enhanced multiple bur hole indirect extracranial-intracranial bypass as 
a novel therapeutic approach in the brain, possibly aiding the treatment of diseases 
such as chronic cerebral hypoperfusion, complex IAs and stroke.  
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Gene symbols are not shown here, all symbols used follow the Human Genome Or-
ganisation (HUGO) guidelines (Wain et al., 2002). 
 
Introduction 
Cerebral vasculature is one of the densest vascular networks in the human body (Pic-
ture 1) (Zlokovic et al., 1998). Cerebral arteries are distinct from their extracranial 
counterparts in multiple ways: their walls are weakened by the lack of the external 
elastic lamina (Nyström, 1963) and they are armoured by strong autoregulation in 
order to keep cerebral blood flow stable (Astrup et al., 1981) within the confined space 
defined by the skull. Sadly, a variety of diseases plague cerebral arteries. 
 
Medical research aspires to decipher pathobiology for the sake of improving prevention 
and patient care. Our understanding of the pathobiology and of possible therapies may 
be advanced by a variety of approaches; such as dissecting genetic susceptibility, under-
standing the functional effect(s) of genetic variants, and by studying the healthy or the 
pathological process in a model organism. The studies summarised here represent 
different sections of this spectrum of approaches. They aim to provide further insight 
into cerebrovascular biology and pathobiology. 
 
Our understanding of the genetic background of diseases has increased considerably 
during the last few decades. The first boom of modern genetics was between the end of 
the 1980s and early 2000s. During this period, the genetic background of monogenic, 
highly penetrant (i.e. Mendelian) diseases was dissected in large numbers (Peltonen et 
al., 1999). Hence, the era may be referred to as the “Mendelian disease boom”. The 
initial success made some believe for a while that understanding of the genetic back-
ground will provide a shortcut to cures. However, it turned out that only some rare 
disorders or rare manifestations of common disorders obey Mendelian rules (Luft, 
2003). Genetic susceptibility of most traits (like height or longevity) and of most com-
mon diseases (such as hypertension, diabetes or intracranial aneurysm) remained elu-
sive at a population level (Schork, 1997). We have witnessed the second boom of mod-
ern genetics in the last seven years. In this new “era of genome-wide association studies 
(GWAS)”, cohort sizes peaked to a new, previously unheard of, level (study participants 
up to 200 000 or more) (Ehret et al., 2011). We gradually learned that in complex 
diseases, each variant contributes only a small individual effect (Hindorff et al., 2009), 
leaving their cumulative effect comparable with that of traditional risk factors, such as 
environmental and lifestyle related risks (Visscher et al., 2012). Furthermore, we came 
to appreciate the importance of the intergenic regions, once referred to as genetic de-
serts (Hindorff et al., 2009). Currently, we are on the verge of a new era, the “post 
GWAS era”, where we search for the contributing variants by sequencing the whole 
exome, or the whole genome of individuals. Publications I-III dissect the genetic sus-
ceptibility to intracranial aneurysm (IA), revealed by the “GWAS era”.  
 
Understanding the mechanism of genetic contribution to disease risk may facilitate 
future prevention. Although studies I-III greatly improved that of IA risk, yet, the most 
efficient currently known preventions are smoking cessation and treatment of high 
blood pressure. When IAs form, however, they often necessitate invasive treatment. 
Most IAs can be surgically directly clipped, or coiled by endovascular means. Complex 
IAs occasionally may require bypass surgery prior to the closure of the vessel segment 
harbouring the aneurysm (Hopkins et al., 1979; Spetzler et al., 1980; Sanai et al., 
2009). Cerebral bypass surgeries remain technically challenging, involving significant 
risks, and are confined to subspecialised centres (Uno et al., 1998; Mesiwala et al., 
2008). 
 
In order to facilitate the development of a technically less challenging cerebral bypass, 
we studied brain angiogenesis in a model animal. Angiogenesis is the vascular growth 
factor promoted formation of new blood vessels from the pre-existing vasculature. 
Publication IV presents an unfolding translational project aiming to harvest decades of 
vascular research in order to utilise vascular growth factors in the central nervous sys-
tem (CNS). Vascular growth factors may boost cerebral bypasses, hence providing a 
new treatment approach for revascularisation. It may be utilised in conditions such as 
chronic cerebral hypoperfusion, seen in diseases like vascular dementia and moyamoya 
disease, or it may be involved in the treatment strategy of complex aneurysms or su-
barachnoid haemorrhage. 
 
In this thesis, I review and present the results of modern genetics in deciphering the 
genetic contribution to IA. Further, I review the role of angiogenesis in biological and 
pathological processes and show how we identified the vascular growth factor most 
suitable for revascularisation of the brain. 
Review of Literature 
1 Special Features of Cerebral Circulation 
1.1 General Features 
 
Picture 1. Vasculature of the brain (modified from (Zlokovic et al., 1998)). 
The average adult human brain is composed of 80-120 billion neurons (Azevedo et 
al., 2009; Herculano-Houzel, 2009) with an actual mass of approximately 1.5 kg 
(Carpenter, 1996). Typically 750 ml of blood rushes through the brain per minute 
(Ito et al., 2003). Hence, the brain, weighing less than 2% of the body’s weight, 
receives 15% of the cardiac output and demands around 20% of the oxygen con-
sumed by the whole body (Kumar et al., 2003). The cerebral blood volume, i.e., the 
volume of blood within the cerebral vasculature at a given time, is approximately 50 
ml, or 3-5% of the total intracranial volume, with significant temporospatial differ-
ences to it (Ito et al., 2003; Sourbron et al., 2009; Krieger et al., 2012). The brain 
and its vasculature is suspended in the cerebrospinal fluid (CSF) which has a net 
weight of around 25 grams (Noback, 2005). 
 
1.2 Cerebral Blood Supply 
The brain derives its blood supply for its dense capillary network (Picture 1) from 
the internal carotid- and vertebral arteries. The internal carotids and their branches 
are referred to as the anterior circulation. The two vertebral arteries unite at the 
caudal border of the pons to form the basilar artery. The vertebrobasilar arterial 
system and its branches are called the posterior circulation of the brain. The ante-
rior and the posterior circulations are joined by the anterior and posterior commu-
nicating arteries in front of the brainstem in the circle of Willis (Willis, 1664).  
 
Global disruption of blood supply to the brain leads to irreversible damage within 
minutes (Astrup et al., 1981; Sakoh et al., 2001; Sobesky et al., 2004). Due to this 
vulnerability, the brain is protected by its autoregulation of blood vessels that pro-
vide a steady blood flow in a wide range of perfusion pressures (Astrup et al., 1981). 
Local interruption of blood flow commonly leads to cerebral ischaemia or stroke 
(Astrup et al., 1981; Sakoh et al., 2001; Sobesky et al., 2004). Though branches of 
the cerebral arteries form anastomoses with each other (Liebeskind, 2003, 2007), 
this is mainly restricted to the surface of the brain in the form of leptomeningeal 
collaterals (Brozici et al., 2003; Kucinski et al., 2003; Alastruey et al., 2007; 
Krishnaswamy et al., 2010). These collaterals have only a limited capability to cor-
rect for a sudden blockage of cerebral arteries (Liebeskind, 2005a; Miteff et al., 
2009). However, if a vessel closes over a long period of time, further collaterals may 
form that may be sufficient to prevent stroke (Schaper et al., 2003; Schaper, 2009; 
Shuaib et al., 2011). There are many physiological variants of the cerebral circula-
tion, leading to different levels of compensatory ability in the case of adverse events 
(Liebeskind, 2005a, b; Miteff et al., 2009; Liebeskind et al., 2010; Shuaib et al., 
2011).  
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1.3 The Blood-Brain Barrier 
 
Figure 1. The schematic ultrastructure of the blood-brain barrier (modified from (Tam et 
al., 2010)). 
 
The CNS is separated from 
the systemic immune system, 
hence it is an immune-
privileged organ, with some 
restrictions to it. Though there 
is a lack of conventional lym-
phatic system, immune cells 
are present in the CNS 
(Carson et al., 2006) and anti-
gens are drained via the CSF 
to the cervical lymph nodes 
(Hatterer et al., 2006). Fur-
thermore, recent results sug-
gest a critical role for astroglial cells in the clearance of interstitial solutes (Iliff et al., 
2012). The most important component of the barrier between the CNS and the 
systemic immune system is the blood-brain barrier (BBB). The BBB is a highly selec-
tive physiological barrier that occurs along the capillaries of the CNS. It consists of 
multiple layers; such as a single layer of endothelial cells joined by tight junctions 
(Risau, 1998), pericytes and astrocyte foot processes (Figure 1).  The complex of the 
BBB is regulated by the pericytes (Armulik et al., 2010). The functional importance 
of pericytes is emphasised by their exceptionally high density in the CNS (Sims, 
1991; Bergers et al., 2005). Disruption of the BBB leads to vasogenic oedema, when 
fluid escapes from the vasculature to the interstitial space (Kumar et al., 2003). 
Vasogenic oedema is seen, for example, with abnormally permeable vessels of ma-
lignant brain tumours, such as high-grade gliomas. 
 
1.4 The Cerebral Artery Wall 
Walls of cerebral arteries, like the walls of extracranial ones, consist of three histo-
logical layers (Figure 2). However, cerebral arteries lack an external elastic lamina, 
and their adventitia is only weakly developed (Nyström, 1963; Stehbens, 1972; 
Ostergaard et al., 1987), leading to an anatomically less firm structure. Furthermore, 
vasa vasori, the small capillaries supplying the blood vessel walls, are rare and con-
fined to the proximal segments of the internal carotid- and vertebral arteries (Aydin, 
1998).  
 
Figure 2. Comparing anatomy of the extracranial and the cerebral arterial walls. 
Extracranial artery wall 
Cerebral artery wall 
Single layer of endothelial cells 
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2 Common Pathologies of the Cerebral Vasculature 
2.1 General Classification of Cerebrovascular Disorders 
Cerebrovascular disorders are a heterogeneous group of diseases affecting the blood 
vessels supplying the brain. Cerebrovascular disorders may be categorised as (1) 
cerebral hypoperfusion (CH), (2) intracranial bleeds and (3) vascular malformations. 
 
Lack of sufficient cerebral blood supply (1), i.e. CH, acutely may lead to ischaemic 
stroke, whereas chronically it is suspected to cause cognitive impairment, such as 
vascular dementia (VD) (Sarti et al., 2002; Ruitenberg et al., 2005). Intracranial 
bleeds (2) may be intracerebral in nature, often due to the harmful effect of sus-
tained hypertension, or the bleeding may be confined to the subarachnoid space, 
referred to as subarachnoid haemorrhage (SAH). The most common cause of SAH 
is the rupture of an IA (van Gijn et al., 2007). The more common forms of intrac-
ranial vascular malformations (3) are arteriovenous malformations (AVM) (Weber 
et al., 2006) and cavernomas (Weber et al., 2006; Vernooij et al., 2007), whereas 
dural arteriovenous fistulae (DAVF) are a more rare pathology (Newton et al., 
1969). 
 
From the common cerebrovascular disorders, this thesis focuses on IA and hypoper-
fusion. 
 
2.2 Intracranial Aneurysms 
The majority (97%) of IAs are berry-shaped pouches at the branching sites of cere-
bral arteries, referred to as saccular IAs (Picture 2). A minority (3%) of IAs are fusi-
form, indicating a dilated arterial segment. Most research, including that presented 
in this thesis, focuses on saccular IA. 
 
 
 
2.2.1 Epidemiology of IA 
IAs are acquired lesions (Rinkel et al., 1998). The prevalence of IA is 2-5% in most 
studied populations (Rinkel et al., 1998; Ronkainen et al., 1998; Vernooij et al., 
2007; Vlak et al., 2011) and will likely never become symptomatic (Brisman et al., 
2006). Up to one third of patients may carry multiple IAs (Inagawa, 1990a; Rinne et 
al., 1994; Ellamushi et al., 2001). The majority of IAs are sporadic, with less than 
10% of patients showing familial 
aggregation (Ruigrok et al., 2005). 
True familial IA, with Mendelian-
like pedigree, is very rare (Verlaan 
et al., 2006; Kim et al., 2011).  
 
Picture 2. Saccular IA (modified 
from: www.swedish.org). 
2.2.2 Rupture of IA causes SAH 
The rupture of an IA is the most common (85%) cause of SAH (van Gijn et al., 
2007). SAH is a devastating form of stroke, the cumulative mortality at six months 
is 50% (Fogelholm et al., 1993; Hop et al., 1997; Pobereskin, 2001; Sivenius et al., 
2004; Stegmayr et al., 2004) and SAH survivors are plagued by a 12% excess mortal-
ity even up to 15 years after the event (Huttunen et al., 2011). Recently, the fatality 
rate of SAH has shown a gradual improvement (Hop et al., 1997; Stegmayr et al., 
2004; de Rooij et al., 2007; van Gijn et al., 2007), still, 10-15% of SAH patients die 
before reaching medical attention (Pakarinen, 1967; Pobereskin, 2001; Huang et al., 
2002). The rupture risk of an IA depends on, among other factors, its size and loca-
tion (Morita et al., 2012).  
 
2.2.3 Epidemiology of SAH 
Though the lifetime prevalence of IA is comparable worldwide (Vlak et al., 2011), 
their rupture rates differ. In most populations the incidence of SAH is 6–10 cases 
per 100 000 person-years (Linn et al., 1996; ACROSS, 2000). However, in Finland, 
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Japan and Northern Sweden the incidence is much higher, being 16–20 cases per 
100 000 person-years (Ohkuma et al., 2002; Sivenius et al., 2004; Stegmayr et al., 
2004). In Finland more people die annually because of SAH than due to traffic 
accidents. In 2010, there were 295 deaths due to SAH compared to 251 deaths 
from traffic accidents (Finland-Statistics, 2010). The reason for this higher-than-
average incidence is unknown, though, it seems to be predominantly due to envi-
ronmental factors (Ruigrok et al., 2001; van Gijn et al., 2007; Korja et al., 2010). 
SAH affects the working age population, with a median age of 55 (Hop et al., 1997). 
The lost years of potential life are significant and similar to those lost to ischaemic 
stroke and intracerebral haemorrhage (Johnston et al., 1998; Rivero-Arias et al., 
2010). Aneurysmal SAH, as a sudden, often deadly disease, places a heavy burden 
on families and the whole society both emotionally and financially (Johnston et al., 
1998). 
 
2.2.4 Risk Factors of IA and SAH 
The risk factors of IA and SAH are overlapping, although appear not to be the same. 
Separating them would be useful, but it is rather difficult, among other factors, due 
to the confounding effect of actively treating unruptured IA. Positive family history 
of IA (Ronkainen et al., 1997), older age and female sex are all non-modifiable risk 
factors of developing IA (Rinkel et al., 1998; Vlak et al., 2011). Of the modifiable 
risk factors, smoking has been shown to increase the risk of IA formation (Juvela, 
2002b), and high blood pressure has long been speculated to do so (Inci et al., 
2000). As for SAH, the strongest non-modifiable risk factor is positive family history. 
Modifiable risk factors of SAH are hypertension, smoking and excessive alcohol 
consumption, with the latter two showing additive effect (Juvela, 2002a, 2003; 
Feigin et al., 2005; Lindekleiv et al., 2012).  
 
2.2.5 Histopathology of IA 
Studying the walls of IAs revealed multiple degenerative changes. The wall of IA is 
often characterised by a damaged endothelium (Scanarini et al., 1978; Kataoka et 
al., 1999; Frösen et al., 2004), by the loss of the internal elastic lamina (Nyström, 
1963; Scanarini et al., 1978; Frösen et al., 2004), and by a disorganised, rather rigid 
medial layer. The elasticity of the medial layer is lost both due to the decreased 
number of vascular smooth muscle cells (Scanarini et al., 1978; Sakaki et al., 1997; 
Frösen et al., 2004; Rajesh et al., 2004) and due to the phenotypic switch in them; 
from contractile towards proliferating type (Nakajima et al., 2000).  
 
Not surprisingly, the walls of ruptured IAs differ greatly from those that are unrup-
tured. Some differences are the consequences of the rupture, however, significant 
differences such as inflammation (Tulamo et al., 2006) and remodelling of the wall 
(Frösen et al., 2004, 2006; Laaksamo et al., 2008), exist prior to the rupture. These 
differences facilitate the classification of IAs according to their tendency to rupture 
(Frösen et al., 2004). Taken together, histopathological and epidemiological 
(Huttunen et al., 2010) evidence suggests that rupture-prone IAs form a distinct 
subgroup. Whether an IA can transform from non-rupture-prone subgroup to the 
rupture-prone one, or vice versa, is therapeutically an important question and is not 
yet well understood.  
 
2.2.6 Diagnosis and Treatment of IA and SAH 
Most IAs present with rupture, causing predominantly SAH. Common clinical 
symptoms of SAH are sudden onset of headache with altered level of consciousness 
or focal neurological deficit (Menghini et al., 2001; van Gijn et al., 2001). The diag-
nosis of SAH is primarily achieved with CT-scan (Adams et al., 1983), however, a 
minor SAH may not be detectable with CT and a lumbar puncture is needed for 
confirmation (Vermeulen et al., 1989). In patients with SAH, IA should be sus-
pected and sought by cerebral angiography (Pedersen et al., 2001). Ruptured, un-
treated IAs carry a high risk of rebleeding, with the peak incidence in the first 24 
hours (Pakarinen, 1967; Kassell et al., 1983; Inagawa et al., 1987; Juvela, 1989).  Up 
to 60% of patients die after rebleeding (Pakarinen, 1967; Kassell et al., 1983; 
Inagawa et al., 1987; Juvela, 1989), hence, the primary aim of SAH treatment is to 
prevent it. IAs can be excluded from the circulation by microneurosurgical or en-
dovascular approaches (Mayberg et al., 1994; Molyneux et al., 2002). Early mi-
croneurosurgical treatment of ruptured IA has been shown to both decrease mortal-
ity and to improve quality of life in the survivors (Öhman et al., 1989; Fogelholm et 
al., 1993). Treatment in specialised centres significantly improves the outcome 
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(Meretoja et al., 2011), however, the strongest predictor of outcome is the patient’s 
neurological grade on admission (Kassell et al., 1990; Saveland et al., 1992; 
Hernesniemi et al., 1993; Osawa et al., 2001; Bracard et al., 2002; Laidlaw et al., 
2003; Weir et al., 2003; Mocco et al., 2006), followed by the patient’s age 
(Rosengart et al., 2007). In Helsinki, with a long and vast experience in vascular 
neurosurgery, microneurosurgical clipping is favoured over endovascular coiling. 
Furthermore, clipping shows better long-term outcomes (Molyneux et al., 2005; 
Pyysalo et al., 2010) and factors concerning aneurysm location favour an open vas-
cular approach in the Finnish population (Dashti et al., 2007). Additionally, the 
surgical treatment of complex IAs might necessitate a bypass procedure prior to 
clipping of the IA sac (Hopkins et al., 1979; Spetzler et al., 1980; Yeh et al., 1997; 
Sanai et al., 2009). 
 
2.2.6.1 Cerebral Vasospasm after SAH 
Cerebral vasospasm refers to the delayed arterial narrowing commonly occurring 
between the fourth and ninth day after SAH (Weir et al., 1978). Angiographic va-
sospasm is common (50-75%) among SAH patients (Kassell et al., 1985; Inagawa, 
1990b), however, it may be clinically silent. Symptomatic vasospasm, on the other 
hand, is associated with delayed ischaemic neurological deficit (DIND) (Haley et al., 
1992; Longstreth et al., 1993), a likely multifactorial, possibly fatal complication. 
Although most treatment options have only limited value, reversal of the arterial 
narrowing, by means such as angioplasty, and hence correcting hypoperfusion can 
prevent ischaemia and reverse neurological deficit (Pluta et al., 2009). The patho-
physiology of cerebral vasospasm and DIND are poorly understood, though, a 
mounting body of evidence support the role of inflammation in the chain of events 
(Dumont et al., 2003; Suarez et al., 2006; Pradilla et al., 2010). The strongest pre-
dictor of vasospasm is the amount of blood on the initial CT scan (Fisher et al., 
1980; Hijdra et al., 1988; Claassen et al., 2001). 
 
2.2.7 Prevention of IA and SAH 
Currently no specific prevention is known for IA formation, and the best preventive 
actions are limited to cessation of smoking (Huttunen et al., 2012) and treatment of 
high blood pressure. In the case of familial IA, i.e. if two or more first degree rela-
tives are diagnosed with IA (Ronkainen et al., 1997), adult family members are 
offered screening, what is shown to be cost effective (Takao et al., 2008). MRA is 
the preferred imaging modality in screening to avoid excess radiation, however, 
smaller IAs may be misdiagnosed, possibly necessitating a CTA for definite diagno-
ses (Numminen et al., 2011). Prevention of the complications of SAH may include 
in the future preventive reperfusion treatment for those at high risk for vasospasm. 
  
2.3 Cerebral Hypoperfusion 
CH refers to the state when the cerebral blood flow is insufficient to meet the needs 
of the brain parenchyma.  
 
In its nature, CH may be: 
 severe or mild, 
 global or localised, 
 permanent or transient, 
 acute or chronic. 
 
2.3.1 Acute Cerebral Hypoperfusion 
In the case of acute cerebral hypoperfusion (ACH), since the insult happens sud-
denly, there is no time for the brain vasculature to adjust and compensate for the 
loss of blood supply. Hence, abrupt occlusion or severe narrowing of a vessel com-
monly leads to ischaemia.  Acute, severe decrease of blood flow to the entire brain, 
if sustained over a few minutes, leads to global hypoxic-ischaemic encephalopathy, 
resulting in death. In contrast, acute, localised decrease of blood flow, if persistent, 
leads to stroke. Vasospasm after SAH often leads to acute localised decrease of 
blood flow and DIND, furthermore, rarely to globally decreased blood flow. If the 
occlusion resolves and the decreased blood flow occurs only briefly, it leads, by defi-
nition, to transient ischaemic attack.  
 
2.3.1.1 Treatment of ACH 
ACH treatment should be prompt and should focus on reopening the occluded 
vessel. The first-line reperfusion therapy in industrialised countries is attempting 
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thrombolysis by recombinant tissue plasminogen activator (Wardlaw et al., 2003), 
followed by endovascular means such as intra-arterial prourokinase treatment, me-
chanical clot retrieval and angioplasty (Adams et al., 2005; Goldstein, 2007). In 
stroke, “time is brain” - in a typical large vessel stroke 120 million neurons are lost 
each hour when untreated (!) (Saver, 2006).  
 
2.3.2 Chronic Cerebral Hypoperfusion 
In chronic cerebral hypoperfusion (CCH), the narrowing or occlusion of the vessel 
occurs gradually, over a long period of time. Hence, corrective mechanisms, such as 
formation of compensatory collaterals may occur, possibly totally offsetting the per-
fusion deficit, and the event of vessel occlusion may remain silent (Schaper et al., 
2003; Schaper, 2009; Shuaib et al., 2011). Unfortunately, this does not always hap-
pen, and CCH may eventually lead to neuronal injury in the area affected (Bennett 
et al., 1998). CCH is commonly seen in the elderly when atherosclerotic plaques 
compromise the cerebral blood flow. Over a long period of time, CCH leads to 
cognitive decline and likely contributes to VD (Ruitenberg et al., 2005) and possibly 
to sporadic Alzheimer disease (AD) (de la Torre, 2000, 2002). These hypotheses are 
confirmed by studies in model animals (de la Torre et al., 1993; Pappas et al., 1996; 
Pappas et al., 1997; Yamada et al., 2011). However, CCH sometimes affects chil-
dren and young adults, typically in the form of the rare moyamoya disease (MMD) 
or syndrome (Scott et al., 2009). In MMD progressive intimal hypertrophy leads to 
the gradual occlusion of the 
ICA and its proximal branches 
(Scott et al., 2009). CCH, by 
exhausting the brain’s compen-
sating capacity, often precedes 
and brings on ACH. 
 
Picture 3. Schematic drawing of 
an STA-MCA bypass (modified from 
(Powers et al., 2011)). 
Text box 
 
2.3.2.1 Treatment of CCH 
Non-invasive treatment focuses on secondary prevention by correcting life-style 
related risk factors and by decreasing general cardiovascular risk with pharmaceuti-
cals, such as ASA and statins. When CCH is due to the atherosclerotic narrowing 
of the extracranial segment of the carotid arteries, the plaques may be removed by 
carotid endarterectomy (Barnett et al., 1998), or alternatively, the ill vessel segment 
may be dilated by stenting (Brott et al., 2010).  
 
The types of cerebral bypass surgeries 
 
 Direct extracranial-intracranial (EC-IC) bypass. The most commonly utilised 
form of it is the superficial temporal artery-middle cerebral artery (STA-MCA) by-
pass (Picture 3).  The technique was first described by Yašargil and co-authors in 
1969 (Crowell et al., 1969). 
 
 Indirect EC-IC bypass is when highly vascularised tissue is brought into straight 
contact with the hypoperfused brain, however, without performing vessel anas-
tomosis. Different methods include EDAS (Matsushima et al., 1990), EDAMS 
(Ishikawa et al., 1997) and multiple bur hole indirect EC-IC bypass (Endo et al., 
1989). 
 
 Direct intracranial-intracranial (IC-IC) bypass is most commonly used when 
reconstructing an ill vessel segment during surgery of complex IA (Sanai et al., 
2009). 
 
 Excimer laser-assisted nonocclusive anastomosis (ELANA) (Streefkerk et al., 
2003) is currently the only technique when temporary occlusion of parent vessels 
is not necessary. It is performed in only a few subspecialised centres, since it is 
technically highly challenging (Vajkoczy et al., 2012). 
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If the ill vessel segment resides intracranially, surgical options are predominantly 
confined to bypass surgery (Text box). In athero-occlusive disease, though tempting 
as it sounds, EC-IC bypass repeatedly failed to prevent stroke more efficiently than 
non-invasive treatments (The-EC/IC-Bypass-Study-Group, 1985; Powers et al., 2011; 
Rodriguez-Hernandez et al., 2011; Komotar et al., 2012). 
 
In the pediatric MMD, indirect EC-IC bypass is sufficient to restore perfusion 
(Ishikawa et al., 1997; Scott et al., 2009). In the case of the adult MMD, indirect 
bypass procedures are inefficient (Houkin et al., 1996). Direct EC-IC bypass proce-
dures may relieve symptoms, though they carry significant risks, such as the hyper-
perfusion syndrome (Uno et al., 1998; Ogasawara et al., 2005; Fujimura et al., 2007; 
Jin et al., 2011).  
 
2.3.3 Risk Factors of Cerebral Hypoperfusion 
Modifiable risk factors of ACH and CCH are the common modifiable cardiovascu-
lar risk factors such as hypertension, smoking, hyperlipidaemia, diabetes mellitus 
and excessive alcohol consumption (Wolf et al., 1991b; Wannamethee et al., 1995; 
Hankey, 1999; Meyer et al., 2000; Vermeer et al., 2002; Reynolds et al., 2003; Patra 
et al., 2010).  Furthermore, atrial fibrillation is an important independent risk fac-
tor for ACH (Wolf et al., 1987, 1991a). Non-modifiable risks are male gender and 
age (D'Agostino et al., 1994; Meyer et al., 2000). Furthermore, when ACH is seen 
with delayed cerebral vasospasm after SAH, the strongest risk factor is thick layers of 
subarachnoid blood on the admission CT scan (Fisher et al., 1980; Hijdra et al., 
1988; Claassen et al., 2001).  
 
 
3 Genetics of Intracranial Aneurysm 
3.1 The Human Genome 
Genome refers to the entire hereditary material of an organism. 
 
3.1.1 The Structure of the Human Genome 
In most organisms, the genetic code is written by the four nitrogenous bases of the 
deoxyribonucleic acid (DNA); adenine, cytosine, guanine and thymine. Two DNA 
molecules join to form a double helix (Watson et al., 1953) which is wound around 
histone beads and superstructured into chromosomes (Figure 3). Most human cells, 
with the exception of germ cells, are diploid, carrying two copies of the 22 auto-
somal chromosomes and a pair of sex chromosomes in their nuclei. The function of 
DNA is to carry the information needed to build and maintain an organism.  
 
Figure 3. Two DNA molecules are held together by hydrogen bonds forming the DNA 
duplex. The DNA double helix is superstructured into chromosomes (modified 
from: www.genome.gov). 
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According to the central dogma of molecular biology; DNA is transcribed into ri-
bonucleic acid (RNA), which is translated into proteins. Hence providing us with 
over 20 000 different proteins, such as structural proteins, enzymes or cell signalling 
molecules. Our genome consists of over 3 billion base pairs, however, only 1.5% of 
it encodes proteins (Lander et al., 2001). The protein coding part of the genome is 
called the exome. The function of the rest of the genome is yet largely unknown, 
although it has been suggested lately to play a regulatory role. 
3.1.2 Common and Rare Variations in the Genome 
During DNA replication, every billionth base is copied with a mistake (Nachman et 
al., 2000; Loeb et al., 2003; Kunkel, 2004). If left uncorrected, mistakes lead to 
genetic variations, referred to as mutations. If the variation contributes to a fitter 
organism it is a progression in the evolution and the mutation will thrive, becoming 
more common with every generation. However, if the “mutant” organism’s survival 
or reproduction is weaker, the mutation’s frequency will be low or it will be purged 
at a population level. When the variation is functionally neutral, it may be carried 
on and randomly distributed among the population. If over 5% of the population 
carries a variation, it is called common. If it is seen with a frequency of 0.5-5%, it is 
referred to as a low frequency variant. If seen in less than 0.5% of the population, it 
is called rare (The-1000-Genomes-Project-Consortium, 2010). When a variant is 
extremely rare, seen maybe in only one family, it is referred to as a private variation. 
Variants with an allele frequency of 1% or higher are commonly referred to as 
polymorphisms (The-1000-Genomes-Project-Consortium, 2010). The most common 
types of polymorphisms in our genomes are single nucleotide polymorphisms 
(SNPs) and small structural variations (Table 1). Common variations are not dis-
tributed equally throughout the genome, but show a reduced frequency in the vicin-
ity of genes (Cai et al., 2009; The-1000-Genomes-Project-Consortium, 2010). 
 
3.1.2.1 Single Nucleotide Polymorphisms (SNPs) 
The nucleotide sequence of the somatic genome differs on average with 0.1% be-
tween humans (Reich et al., 2002). One in every 100 to 300 base pairs may be vari-
able (The-1000-Genomes-Project-Consortium, 2010). Single nucleotide variations 
are referred to as single nucleotide polymorphism (SNP, pronounced “snip”) if over 
1% of the population carries them. The function of SNPs is not fully understood as 
yet, although they appear to regulate gene expression (Stranger et al., 2007). SNPs, 
by giving close to accurate genome-wide information without the need for sequenc-
ing the whole genome, facilitated the development of the human genome’s haplo-
type map (The-International-HapMap-Consortium, 2003, 2005; Frazer et al., 2007; 
Altshuler et al., 2010). Furthermore, GWAS that seek common genetic susceptibil-
ity to common diseases, utilise SNPs as genetic markers. 
Table 1. Overview of most common genetic variations.  
  STRUCTURAL VARIATIONS 
 SNP Indels CNV Chr. Abn. 
Size 1 bp 1 bp-1 kb 1 kb- 3 Mb >3 Mb 
Number/genome*  millions 100 000-500 000 5-50 0-few 
Phenotypes/Diseases 
examples 
numerous traits 
/diseases 
less well described 
neurodevelop-
mental disorders, 
cancer 
syndromic 
disorders 
* Numbers are averaged estimates based on multiple publications. Chr. Abn.= 
chromosome abnormalities.  
 
3.1.2.2 Structural Variations 
Variations often encompass more than a single polymorphic base pair (Table 1). 
These are referred to as structural variations (Iafrate et al., 2004; Conrad et al., 
2006; Feuk et al., 2006; Redon et al., 2006). Classically structural variations are 
defined to be between 1kb to 3Mb in length and are called copy-number variations 
(CNVs). However, some are smaller than 1 kb, these are typically small inser-
tions/deletions, i.e. indels. Most structural variations and all indels are submicro-
scopic. The variations greater in length than 3 Mb are the classical microscopic 
chromosomal abnormalities. Structural variations may cover 13% of the human 
genome (Stankiewicz et al., 2010) and account for most interindividual differences 
of the genome (Conrad et al., 2010), that are on average 1.5% (Pang et al., 2010). 
 
By their nature, structural variations may be balanced or unbalanced. Balanced 
variations, where no DNA segment is lost or added, include inversions and some 
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translocations (Figure 4). On the other hand, the most common form of unbal-
anced structural variation is CNVs, where a DNA segment is either lost (deletions), 
or multiplied (duplications, triplications etc.) (Figure 4). Smaller variations, such as 
short indels and small CNVs, are significantly more common than larger structural 
variants (Table 1) (The-1000-Genomes-Project-Consortium, 2010). CNVs tend to 
affect the expression levels of nearby genes, and they are suspected to shape the 
tissue transcriptome (Stranger et al., 2007; Henrichsen et al., 2009). CNVs most 
often form as a replication mistake when highly similar but non-related regions are 
joined (Hurles, 2005; Conrad et al., 2010). CNVs can be de novo, however, an over-
whelming majority are inherited, hence, CNVs are plausible candidates for explain-
ing heritability (McCarroll, 2008; Craddock et al., 2010). Nevertheless, common 
CNVs were found to have only a small effect on complex disease risk (Conrad et al., 
2010; Anney et al., 2012). 
 
Figure 4. Examples of structural variations in the human genome (modified from: 
www.genome.gov). 
3.1.3 Heritability 
Nature (genes) and nurture (environmental and life-style related factors) together 
determine most traits. Commonly, a trait is referred to as a “genetic” one, when 
there is a significant genetic contribution to its risk. Nevertheless, one should bear 
in mind that most of our traits and diseases are shaped by genetic contribution, to 
different extents.  
 
The heritability of a trait or a disease is the proportion of the total variation that can 
be attributed to genetic factors (Visscher et al., 2008). Given its definition as the 
proportion of the variation, the value of heritability always lies between 0 and 1 
(Wray et al., 2008). For instance, the heritability of height in humans is estimated to 
be 0.8 (Macgregor et al., 2006), however, for most traits associated with fitness, 
heritability is typically 0.1-0.2 (Figure 5) (Visscher et al., 2008). If one could elimi-
nate all contributing environmental and life-style related factors, heritability would 
be 1, meaning that the trait would only be expressed by those that have a strong 
genetic susceptibility to it. Since environmental and life-style habits may change over 
time and are different between populations, heritability tends to be time- and popu-
lation specific (Visscher et al., 2008).  
 
Figure 5. Comparing the heritability of traits and diseases (Heikkila et al., 1989; Czene et 
al., 2002; Agarwal et al., 2005; Walley et al., 2006; Lessov-Schlaggar et al., 2008; 
Silventoinen et al., 2008; Asthagiri et al., 2009; Stacey et al., 2009; Korja et al., 
2010). As of today, the heritability of IA is unknown. 
Heritability of a trait can be estimated by the help of family- and twin studies, and 
by measuring inter-ethnical differences. If genetic factors confer risk for the disease, 
closest relatives should display increased risk, which decreases toward the popula-
tion prevalence for more distant relatives. Familial aggregation of a disease makes 
genetic contribution likely, but since most family members share environment as 
well, the two cannot be easily separated. Traditionally, heritability was estimated 
from study designs such as measuring the difference in phenotypic correlation of 
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monozygotic and dizygotic twin pairs (Wray et al., 2008). However, new methods 
have emerged estimating heritability with the help of genetic markers, by defining 
the proportion of the genome shared identical-by-descent (Visscher et al., 2006). 
When aiming to define the heritability of a trait or disease, factors such as the acces-
sibility of it (eg. height is easily accessible in contrast with IAs that are “hidden” by 
the skull) or whether affected-unaffected status may change over time, can be cru-
cial. As of today, we do not know the heritability of IA since the phenotype is diffi-
cult to access and affected-unaffected status may be time dependent. Currently there 
are no large twin- or migrant cohorts characterised for IA. The heritability of IA 
rupture leading to SAH is rather low (Korja et al., 2010).  
 
3.2 Mendelian Genetics 
Gregor Johann Mendel, the founder of genetics, was an Austrian scientist and an 
Augustinian monk in the XIXth century (Picture 4). 
 
Picture 4. Gregor Johann Mendel (modified from: www.wikipedia.org). 
3.2.1 Mendelian Diseases 
Mendel studied the inheritance of certain traits in pea plants and based on those 
results, formulated the “Law of Segregation” (aka. First Law of Mendel), and the 
Law of Independent Assortment (aka. the Second Law of Mendel). The traits he 
studied were monogenic with perfect penetrance, meaning that a particular geno-
type at one locus is both necessary and sufficient to create the trait. Such traits are 
referred to as Mendelian, since they obey the laws of Mendel, and are examples of 
the rare genetic determination. 
 
Figure 6. An example of an autosomal dominant Mendelian disease pedigree (A) (modi-
fied from (Fournier et al., 2001)) and a typical IA pedigree (B) (modified from: 
(Ruigrok et al., 2004b)). Arrows mark “index” patient (who brought the atten-
tion to the family), deceased individuals are marked with a diagonal line, ques-
tion marks refer to unknown disease status. 
The online catalogue of Mendelian diseases in humans (OMIM) currently lists ap-
proximately 4000 diseases. Mendelian diseases can be recognised from their charac-
teristic pedigree patterns (Figure 6A). Extended pedigrees showing Mendelian in-
heritance in IA are extremely rare (Verlaan et al., 2006; Kim et al., 2011). Most IA 
pedigrees include just a few affected individuals in one, or possibly two generations 
(Figure 6B), where lack of diagnostic tools in the earlier times, or very young age in 
the newest generation, limit identification of affected individuals. 
 
3.2.2 Linkage and Linkage Disequilibrium 
Meiotic recombination during chromosomal crossing over is the exchange of ge-
netic material between homologous chromosomes (Creighton et al., 1931). Since 
the number of recombination events in a generation is rather small (Visscher et al., 
2012), offsprings inherit long stretches of DNA from the parental chromosomes. 
A B
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Despite the fact that DNA segments tend to break up over many generations, even 
apparently unrelated individuals share recognisable segments of their genome. The 
regions of the chromosome that have not been broken up by recombination events 
are called haplotypes. 
 
Linkage describes the genetic relationship between two loci (Morton, 1956). It refers 
to two loci being inherited together more commonly than expected by chance, i.e. 
recombination rarely separates them. Physical proximity is the most common cause 
of linkage, however, far apart loci might be linked as well. If two loci are in linkage, 
we observe linkage disequilibrium (LD) between them, i.e. they are co-inherited in a 
non-random way. LD occurs as haplotype blocks that are regions of the genome 
with little recombination events. The extent of LD depends on population history, 
hence varying from population to population (Reich et al., 2001a; The-
International-HapMap-Consortium, 2005). The range of LD is shorter in older 
populations, typically among the Africans, and more extensive among younger 
populations characterised by multiple bottlenecks and rapid expansion, such as the 
Finns (Varilo et al., 2003; Service et al., 2006).  
 
Genetic linkage studies in families rely on the co-inheritance, i.e. LD between the 
putative causative variant and genotyped markers. Due to the limited number of 
recombination events, haplotype blocks are large and often it is sufficient to geno-
type a relatively small number of markers per chromosome. The disadvantage of the 
small number of recombination events is that the resolution of these studies is often 
low. Nevertheless, linkage studies have been highly successful in mapping variants 
affecting Mendelian, i.e. single-gene disorders (Botstein et al., 2003). A supreme 
example of the success of linkage studies is the identification of the genes underly-
ing rare, Mendelian disorders that are enriched in the Finnish population isolate.  
 
3.2.2.1 The Finnish Population Isolate 
Nearby populations have often mixed throughout history, decreasing their genetic 
differences. There are a few special cases in which populations remained isolated 
due to cultural, historical or geographical reasons. The Finns, French Canadians 
and the Ashkenazi Jews are examples of population isolates, which have proven to 
be invaluable in dissecting genetic background of rare diseases.  
 Currently, it is believed that Finland was first settled some 4000 years ago by eastern 
Uralic speakers, followed by approximately 2000 years ago by Indo-European speak-
ers (Nevanlinna, 1972; de la Chapelle, 1993; Peltonen et al., 1995). For long centu-
ries only a narrow strip was inhabited on the coastal south and southwest by a small 
number of settlers (Sajantila et al., 1996). The population was likely only around 50 
000 in the XIIth century carrying only a limited genetic pool, reaching 250 000 in 
the XVIth century (Peltonen et al., 1999). Inter-
nal migration from the coastal regions towards 
the north and inner lands started in the XVIth 
century, both to gain land for cultivation and to 
escape taxation from the Swedish Crown 
(Peltonen et al., 1999) (Figure 7).  
Figure 7. Inner migration from the early coastal 
settlements towards the inland in the XVIth century 
(modified from: (Peltonen et al., 2000)). 
Both paternally inherited Y chromosome haplo-
types and maternally inherited mitochondrial 
DNA show an exceptionally low genetic diver-
sity in the Finns (Sajantila et al., 1996). Genea-
logical records kept by the Lutheran church 
since the XVIIth century facilitated genetic re-
search (Norio, 2003b). Researching genetic 
diseases in a population isolate does not only 
benefit the isolate, since results may highlight the pathological pathway(s) involved 
worldwide (Lifton et al., 2001). This was well demonstrated by the discovery of the 
breast cancer gene mutations (BRCA1 and BRCA2), predominantly seen in the 
Ashkenazi Jews (Rubinstein, 2004). Furthermore, complex disease may have a more 
simple genetic background in population isolates that went through multiple bot-
tlenecks, due to the lower amount of variations available. Hence, population isolates 
are believed to facilitate the mapping of complex disease loci or pathways (Peltonen 
et al., 2000).  
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3.2.2.2 Finnish Disease Heritage 
One of the best-known reflections of the bottleneck effect is the Finnish Disease 
Heritage (FDH), dominated by recessive Mendelian disorders due to rare alleles. If 
the limited number of founders of Finland happened to carry mutations for certain 
genetic diseases, the disease will be enriched in the population. In the genetically 
well-studied Finnish population, this unique group of diseases is called the FDH. 
Conversely, there are conditions like cystic fibrosis or phenylketonuria, that are 
commonly seen worldwide, but rarely in Finland (Peltonen et al., 1999). FDH con-
sists of almost 40 hereditary diseases (Norio, 2003a; Finnish-Disease-Database, 
2012). The first disease of the FDH, the congenital nephrosis of the Finnish type, 
was described already in the 1940s and characterised in the 1960s. Carrier frequen-
cies and geographical distribution of FDH mutations vary, among other factors, 
depending on the time of their introduction to the Finnish population (Pastinen et 
al., 2001). Common ones, with as-
sumed early introduction, such as the 
mutation responsible for aspartylgluco-
saminuria (AGU), show rather even 
distribution throughout the country 
with high carrier frequency (1:65) 
(Peltonen et al., 1999). Whereas the 
mutation causing the Finnish variant of 
late infantile neuronal ceroid lipofusci-
nosis (vLINCL) is assumed to be a 
young mutation, with its carriers clus-
tering in southern Botnia. The carrier 
frequency of the vLINCL mutation for 
the whole country is 1:120 (Peltonen et 
al., 1999). One in three Finns is estimated to carry an FDH mutation (Pastinen et 
al., 2001). Most FDH diseases were characterised in the 1990s (Figure 8) by the late 
Academician of Science, Professor Leena Peltonen-Palotie, utilising the extended 
LD characteristics of the Finnish population.  
 
Finland, Finland, Finland 
The country where I want to be… 
You’re so near to Russia  
So far from Japan… 
You’re so sadly neglected 
And often ignored… 
Finland, Finland, Finland 
Finland has it all. 
-Monty Python, “Finland” 
 
 Figure 8. Perheentupa’s steps, showing the year of the first Finnish publication of the 
FDH diseases (modified from: Finnish Disease Database; www.findis.org).  
3.3 Genetics of Complex Diseases 
3.3.1 Complex Diseases 
Monogenic traits proved too fragile from an evolutionary point of view, and as an 
insurance, information about most traits is divided into hundreds of loci with small 
individual effect. Hence, most human traits and diseases are not Mendelian in na-
ture, and their manifestation is likely affected by a large number of genes and modi-
fied by multiple environmental factors (Table 2). In complex traits, individual geno-
typic variants are neither necessary nor sufficient to create the trait (Visscher et al., 
2012). No matter how many genetic or environmental factors contribute to it, the 
trait or disease may be dichotomous in its nature, such as IA (one either has or does 
not have an IA), or continuous, such as blood pressure (it may take any value on a 
continuous scale). Genes or genetic loci underlying dichotomous characters are 
called susceptibility loci. In the case of continuous characters, they are referred to as 
quantitative trait loci. The scientific community has put great effort into identifying 
these loci with significant success (Hindorff et al., 2009). These loci, obvious by the 
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nature of their discovery, do not usually contribute to disease risk significantly at an 
individual level, but their significance lies in increasing disease risk at a population 
level and by enlightening disease related pathways (Huang et al., 2001; Hirschhorn 
et al., 2002; Hirschhorn, 2009).  
Table 2. Comparison of Mendelian and complex diseases.  
 Diseases 
 Mendelian Complex 
Prevalence low low-high 
Penetrance high medium-low 
Familial aggregation enigmatic less evident 
Twin concordance high medium-low 
Number of genes involved one-few multiple 
Effect of environmental factors small large 
Clinical manifestation uniform varying 
 
3.3.2 Susceptibility 
Influenced by both genetic and environmental factors, susceptibility refers to an 
individual’s increased likelihood to develop a particular disease.  
 
3.3.3 Association and GWAS 
Linkage studies and candidate gene studies failed to yield results in complex dis-
eases, due to the likely small effect of individual genes/variants (Hirschhorn et al., 
2002). However, it was still possible that the magnitude of the variants’ cumulative 
effect would be significant. In the mid 1990s Risch and Merikangas proposed that 
association scan of a million variants over the genome, in a cohort of unrelated 
individuals, could be a more powerful tool than linkage analysis (Risch et al., 1996). 
Association is not a specifically genetic phenomenon, it is a statistical statement, 
referring in genetics to the co-occurrence of alleles and phenotypes. It took ap-
proximately 10 years for the idea of Risch and Merikangas to materialise. GWASs 
utilise LD between SNPs at the population level (Visscher et al., 2012). The differ-
ences of linkage and association analyses are summarised in Table 3.  
 
The discovery of SNPs was accelerated by the sequencing of the human genome 
(Lander et al., 2001; Venter et al., 2001), and their LD was quantified by the Hap-
Map project (The-International-HapMap-Consortium, 2005).  At the same time, 
technological advances and biobanks facilitated the ability to conduct GWASs. 
GWAS is a hypothesis generating approach, since it is unbiased with respect to the 
genetic location of the putative causal variant, unlike, for example, candidate gene 
studies. Nevertheless, GWAS is not free of a priori assumptions. By the design of the 
study, GWAS is only powered to detect relatively common causal variants (Visscher 
et al., 2012). 
Table 3. Comparing linkage and association analyses (modified from 
(Molyneux et al., 2002).  
Property of mapping 
approach 
Linkage analysis Association analysis 
Data type studied Relatives 
Unrelated or related  
individuals 
Biological basis of  
approach 
Observe (or infer) recombi-
nation in pedgree data 
Exploit unobserved re-
combination events in 
past generations 
Relevant parameter Recombination fraction Association statistics 
Range of effect detected Long (>5Mb) Short (<100kb) 
Number of markers 
required for genome-wide 
coverage 
Moderate (500-1000) Large (>100 000) 
Statistics used 
Requires tailor-made  
likelihood methods 
Can use the range of  
classical statistical tools 
Genotyping errors Potentially detected Often undetected 
Most suitable application Rare, dominant traits Common traits 
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3.3.3.1 The Dawn of the “GWAS era” 
An early attempt to test the GWAS approach was made in 2002 (Ozaki et al., 2002). 
A few years later, the group led by Josephine Hoh at Yale University conducted the 
first highly successful GWAS (Klein et al., 2005). They identified the complement 
factor H (CFH) polymorphism behind age-related macular degeneration (AMD). 
Their sample size was minute compared to current studies (96 cases and 50 con-
trols) and they “only” tested a little over 110 000 SNPs genome-wide. However, 
AMD happened to be a disease with a strong single locus genetic contribution to its 
risk. Their success fired up the scientific community and hence the “GWAS era” 
began. Manhattan plots, named after resembling the Manhattan skyline, became an 
enigma of the era (Figure 9). The first landmark study of the era was conducted by 
the Wellcome Trust Case Control Consortium, studying seven common diseases in 
14 000 individuals, with shared controls (Wellcome-Trust-Case-Control-
Consortium, 2007).  
 
Figure 9. Manhattan plot of GWAS on AMD. Horizontal dashed line shows the cutoff 
for P = 0.05 after Bonferroni correction. The green arrow points out the sole 
significant association peak with the CFH gene (modified from (Klein et al., 
2005)). 
3.3.3.2 The Fruits of the “GWAS era” in a Nutshell 
As of today, over a thousand GWASs have been conducted (Hindorff et al., 2012) 
and well over 2000 loci have been found to show significant and robust association 
with one or more complex traits (Visscher et al., 2012). Typically, the significantly 
associated SNPs together explain only a small proportion (<10%) of the genetic 
variation for most complex traits or diseases. For certain quantitative traits, how-
ever, GWAS identified loci account for up to 10-20% of their genetic component 
(Visscher et al., 2012).  
 
Furthermore, GWASs have taught us important lessons about the likely nature of 
complex traits and diseases. These lessons are, among others, the following: (1) in 
complex traits the number of contributing loci is high, significantly higher than 
estimated earlier. (2) There are risk loci where multiple alleles associate with disease 
risk. (3) The same variant may associate with multiple traits in a pleiotropic way 
(Manolio, 2010; Sivakumaran et al., 2011). (4) Some risk variants confer risk in 
multiple ethnicities (Visscher et al., 2012). 
 
GWASs are significant investments, Visscher and colleagues estimate the price of a 
discovered locus to be $125 000 (Visscher et al., 2012). Nonetheless, this invest-
ment will likely pay itself back in the form of more cost-efficient public health deci-
sions, due to improved understanding of basic biological disease mechanisms. 
 
3.3.3.3 The Multiple Testing Problem 
The null hypothesis of every GWAS is that there is no association between the trait 
or disease of interest and any of the SNPs tested. Nowadays, up to 1 million SNPs 
are commonly tested for association genome-wide, tagging most common variations 
in non-African populations (The-International-HapMap-Consortium, 2005). This 
high number of tests (106), although not all independent, means that the likelihood 
of type I (false positive) error is significant. Hence, results have to be corrected for 
multiple testing. The most conservative method is the Bonferroni correction 
(Bonferroni, 1935). The Bonferroni correction sets the significance threshold of a 1 
million SNP GWAS to 5x10-8, calculated as the commonly accepted significance 
threshold (0.05) divided by the number of tests performed (106). However, there are 
alternative methods that take into consideration that the tests in the GWAS are not 
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all independent, hence aiming to lower the rate of the type II (false negative) errors. 
Such methods include the computationally demanding permutation tests (Churchill 
et al., 1994), or measuring statistical significance based on false discovery rate 
(Storey et al., 2003) or with the help of the Bayes factor (Wakefield, 2007). Never-
theless, the stringent cut-off of 5x10-8 is still often applied to GWAS. Additional 
approaches to overcome the multiple testing problem include the replication of 
results in independent cohorts and functional studies (McCarthy et al., 2008). 
 
3.3.3.4 The Missing Heritability Problem  
GWASs have greatly improved our understanding of the genetic bases of disease 
risk, even though they tend to identify only a fraction of the specific causal loci, 
hence leaving a significant part of the heritability unexplained (Maher, 2008; 
Manolio et al., 2009; Gibson, 2011). This unexplained portion is often referred to 
as the “missing or hidden heritability”. At the end of the 1990s and the beginning 
of the 2000s, many hypothesised that common diseases are likely to be caused by 
common variants (Lander, 1996; Reich et al., 2001b; Pritchard et al., 2002; Botstein 
et al., 2003).  It became evident that a few dozen loci of moderate effect and inter-
mediate frequency will not explain the genetic risk to most common diseases. Cur-
rently there are three main hypotheses explaining where the hidden heritability may 
lie: (1) there might be a large number of small-effect variants of different frequencies 
(Visscher et al., 2008; Lango Allen et al., 2010), (2) a large number of large-effect 
rare variants (Cirulli et al., 2010), supported by the fact that low-frequency and rare 
variants vastly outnumber common variants (The-1000-Genomes-Project-
Consortium, 2010), or (3) the hidden heritability may lie in the combination of 
genotypic, environmental and epigenetic interactions (Feldman et al., 1975; Eichler 
et al., 2010). Possibly, the mixture of all three. Large-scale whole-exome and whole-
genome sequencing studies may aid us in decreasing missing heritability.  
 
3.4 Studies on the Genetics of IA Before the “GWAS Era” 
Familial aggregation of a disease is suggestive of a genetic contribution to the risk 
(Norrgard et al., 1987). Although only a minority of IAs show familial aggregation, 
10% of patients with aneurysmal SAH have first or second degree relatives with 
SAH or unruptured intracranial aneurysms (Ronkainen et al., 1993; Bromberg et 
al., 1995; Schievink et al., 1995; Wang et al., 1995; De Braekeleer et al., 1996; 
Ronkainen et al., 1999; Wermer et al., 2003). This, and the fact that familial pre-
disposition is the strongest risk factor for developing IA (Rinkel et al., 1998; 
Ruigrok et al., 2001), provoked a Mendelian hypothesis in search of IA genes. The 
tools were limited by the era to linkage analysis and candidate gene studies. 
 
3.4.1 Linkage Studies 
Familial aggregation of IA was noticed already in 1954 (Chambers et al., 1954), 
however, as mentioned above, true familiar IA is rare and likely it is rather different 
from the sporadic disease, as seen with other phenotypes (Lifton et al., 1992; 
Shimkets et al., 1994). Indeed, familial IAs seem to behave clinically distinctly. Fa-
milial IA patients more commonly carry multiple IAs (Ruigrok et al., 2004a) and 
their IAs tend to rupture at a younger age (Leblanc, 1996; Ohashi et al., 2004). 
Nevertheless, the search for IA kindreds has been very active since the 1990s 
(Schievink et al., 1994). Linkage studies were hampered by over-simplistic hypothe-
ses assuming Mendelian inheritance (Wills et al., 2003) and by inaccurate phenotyp-
ing, both due to the relative novelty of diagnostic tools and due to change in case-
control status over time (Roos et al., 2004).  
 
Linkage scans identified multiple loci with strong or suggestive linkage but only a 
fraction of them replicated in other cohorts (Table 4). This might reflect true locus 
heterogeneity, since mutations might be family/region-specific, however, a fraction 
of the loci are likely to have arisen from false positive results. Unfortunately, linkage 
studies failed, thus far, to identify underlying mutations. Table 4 summarises the 
results of most genome-wide and replication linkage scans performed in IA families.  
Table 4. Genetic linkage studies identifying suggestive IA loci.  
Chr band Mb LOD/P Series Populations* 
1p36.1  18.6-24.9 3.18 Ruigrok et al., 2008 Dutch 
1p36.1–34.3 19.6–35.1 4.2 Nahed et al., 2005 US 
1p33 46.6 0.037 (P) Onda et al., 2001 Japanese 
Review of Literature 
 
 The Neurosurgery Research Group 
Emília Ilona Gaál/2012 
51 Intracranial aneurysm genetics and  
growth factor induced CNS angiogenesis 
 
1p22.1 93 0.022 (P) Onda et al., 2001 Japanese 
2q13 112.7 0.044 (P) Onda et al., 2001 Japanese 
3q29 198.5 0.014 (P) Onda et al., 2001 Japanese 
4p16.1–15.3 6.7-13.3 1.27 Olson et al., 2002 Finnish 
4q34.1 174.8 0.04 (P) Onda et al., 2001 Japanese 
5p15.2–14.3 9.4-21.1 3.6 Verlaan et al., 2006 French Canadian 
5q14.3-5q15 85.4-95.8 0.001 (P) Onda et al., 2001 Japanese 
5q22–31 
118.9–140.9 2.24 Onda et al., 2001 Japanese 
111.5-159.9 2.91 Santiago-Sim et al., 2008 French Canadian 
6q14.1 77.6 1.2 Olson et al., 2002 Finnish 
7p22.2 4.2 1.67 Olson et al., 2002 Finnish 
7p14.1 38.96 0.032 (P) Onda et al., 2001 Japanese 
7q11 
71.1–92.3 3.22 Onda et al., 2001 Japanese 
97-104 2.34 Farnham et al., 2004 US 
7q21.1 77.5-88.1 0.021 (P) Onda et al., 2001 Japanese 
7q22.1 101.3 0.014 (P) Onda et al., 2001 Japanese 
7q34 139.4 0.9 Olson et al., 2002 Finnish 
8p22.2 11.28 3.61 Kim et al., 2011 South-Korean 
9p24.2 3.9 0.011 (P) Onda et al., 2001 Japanese 
9p23 9-14.1 2.93 Santiago-Sim et al., 2008 French Canadian 
11p15 5.9 ≈2 Mineharu et al., 2007 Japanese 
11q13.2 67.6 0.042 (P) Onda et al., 2001 Japanese 
11q25 
125–131 4.3 Ozturk et al., 2006 US 
131.2 0.023 (P) Onda et al., 2001 Japanese 
12p12 14.8-26.3 3.1 Santiago-Sim et al., 2008 French Canadian 
13q14.2 
47.8 0.034 (P) Onda et al., 2001 Japanese 
45.1-57.4 4.56 Santiago-Sim et al., 2008 French Canadian 
14q22 
63.6-87.6 3 Ozturk et al., 2006 US 
69.6–77.6 2.31 Onda et al., 2001 Japanese 
14q34.2 99.7 1.36 Olson et al., 2002 Finnish 
17p12-q11.2 14.2–27.1 3 Yamada et al., 2004 Japanese 
17q11.2 24.3 0.027 (P) Onda et al., 2001 Japanese 
18p11 
0.6 0.049 (P) Onda et al., 2001 Japanese 
pter-16.1 3.15 Santiago-Sim et al., 2008 French Canadian 
19q13.3 
38.7–55.6 2.58 Olson et al., 2002 Finnish 
39.8–57.4 3.16 van der Voet et al., 2004 Finnish 
46.7–54 2.15 Yamada et al., 2004 Japanese 
46.7-48.3 4.1 Mineharu et al., 2007 Japanese 
Xp22.2 
14.4 2.08 Olson et al., 2002 Finnish 
14.4–21.8 2.16 Yamada et al., 2004 Japanese 
4.-13.1 4.54 Ruigrok et al., 2008 Dutch 
Mb, physical position is specified with the help of markers identified in the original publications, with 
relaxed criteria of linkage. LOD/P-values are the maximum values reported for the region by the study 
referenced.  P-values are marked with a (P) after them. Regions showing LOD>4 or P<0.01 in at least one 
study, are marked with dark green and the corresponding LOD/P is in bold and underlined.  
*Populations refer to the nationality of the studied families, or when not specified, the nationality of the 
study. 
 
3.4.2 Candidate Gene Studies 
Typical candidate genes of IA have a known or proposed function in the vessel wall, 
such as the collagens or elastin. Alternatively, candidate genes may have an indirect 
effect on vessel wall, such as extracellular matrix proteins. Some candidate genes are 
positional candidates, meaning that linkage studies highlighted the region from 
where the biologically most plausible gene was further studied as a candidate gene. 
Further hypotheses that supported the candidate gene theory are genetic diseases, 
such as type IV Ehlers Danhlos syndrome (EDS-IV) appearing to show a higher-
than-average prevalence of IA. Unfortunately, regardless of the great numbers of 
studies performed (Kuivaniemi et al., 1993; Brega et al., 1996; Schievink et al., 
1996; Takenaka et al., 1999; van den Berg et al., 1999; Yoon et al., 1999; Peters et 
al., 2001; Zhang et al., 2001; Hofer et al., 2003; Krex et al., 2003; Yoneyama et al., 
2003; Hofer et al., 2004; Kassam et al., 2004; Krex et al., 2004a; Krex et al., 2004b; 
Ruigrok et al., 2004c; Yoneyama et al., 2004), candidate gene studies have also 
failed to identify a bona fida causative variant, similar to most candidate gene studies 
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of other disorders (Hirschhorn et al., 2002; Tabor et al., 2002). The most studied IA 
candidate genes are summarised in Table 5.  
 
Table 5. Most studied IA candidate genes (modified from (Ruigrok et al., 2005)). 
Candidate gene Chromosomal band Linkage studies Populations* 
Elastin 7q11.2 Onda et al., 2001 
Japanese 
Dutch 
German 
Collagen type 3 A2 2q31 N/A 
US 
Dutch 
mixed 
Collagen type 1 A2 7q22.1 Onda et al., 2001 Japanese 
Lysyl oxidase 5q22.3–q31.2 Onda et al., 2001 
Japanese 
German 
Fibrillin 2 5q23–q31 Onda et al., 2001 Japanese 
α1 antitrypsin 14q32.1 N/A US 
MMP-9 20q11.2–q13.1 N/A 
US 
UK 
Finnish 
German 
MMP-1, MMP-3, 11q22–q23, 11q23, 
N/A 
UK 
MMP-12 11q22.2–22.3 Finnish 
TIMP-1, TIMP-2, 
TIMP-3 
Xp11.3–p11.23, 17q25, 
22q12.1–q13.2 
N/A German 
If the candidate gene is a positional candidate the original study is identified in the Linkage study 
column. 
*Populations refer to the nationality of the studied subjects in whom the candidate genes were 
tested, or when not specified, the nationality of the study. MMP: matrix metalloproteinase, TIMP: 
tissue inhibitor of MMP. 
 
3.4.3 Associations with Other Disorders  
Since the mid 1980s, familial IA was already noticed to sometimes associate with 
other disorders, such as Marfan’s syndrome (ter Berg et al., 1986; van den Berg et 
al., 1996; Pfohman et al., 2001). Hence, further syndromes affecting the extracellu-
lar matrix proteins like EDS-IV (de Paepe et al., 1988), fibromuscular dysplasia 
(Cloft et al., 1998) and glucocorticoid remediable aldosteronism (Litchfield et al., 
1998) were suspected to increase the risk of IA. Although EDS-IV may increase the 
risk of fusiform aneurysms (Pepin et al., 2000), currently, there is only evidence for 
autosomal dominant polycystic kidney disease (ADPKD) to associate with saccular 
IA (Chapman et al., 1992; Lozano et al., 1992; Schievink et al., 1992; Schievink, 
1997; Belz et al., 2001; Torres et al., 2001). 
 
Up to 10% of ADPKD patients harbour IA, however, it only accounts for less than 
1% of all SAH (Ruigrok et al., 2001; Gieteling et al., 2003). The two genes mutated 
in ADPKD are PKD-1 (Peral et al., 1997) accounting for around 85% of the cases, 
and PKD-2 (Veldhuisen et al., 1997) accounting for the rest. IAs occur in patients 
with mutations in both genes and the precise mechanism is yet unknown, however, 
one can speculate that the effector is likely situated downstream in the common 
pathway. Intriguingly, PKD-1 mutation carrier patients with IAs were significantly 
more likely to carry germ-line mutations in the 5′half of the gene when compared 
to those without IAs (Rossetti et al., 2003; Gibbs et al., 2004; Ong, 2009). 
 
3.5 9p21, the First Common Susceptibility Locus for IA 
Just on the dawn of the first GWAS on IA (I), the Icelandic deCODE group suc-
cessfully identified 9p21 as the first common IA susceptibility locus in a multina-
tional cohort, including Finnish patients (Helgadottir et al., 2008). In 2008, 9p21 
was a susceptibility locus for coronary artery disease and type 2 diabetes (McPherson 
et al., 2007). Little did we know how greatly important this locus would prove to be 
(Figure 10) (Helgadottir et al., 2007; Cunnington et al., 2010; Laaksovirta et al., 
2010; Visel et al., 2010; Harismendy et al., 2011; Shea et al., 2011). Interestingly, 
Helgadottir and colleagues tested and found association at 9p21 with both saccular 
IA and abdominal aortic aneurysm (AAA). Although sometimes co-existing clini-
cally (Nahed et al., 2005), IA and AAA are likely results from different underlying 
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disease processes (Humphrey et al., 2008), though with possible overlapping genetic 
background (Shibamura et al., 2004). 
 
 
Figure 10. Association with multiple diseases at the 9p21 locus (modifeid from (Zeller et 
al., 2012)). CAD: coronary artery disease, T2D: type 2 diabetes. Genes are re-
ferred to by their HUGO symbols. 
3.6 Genetics of SAH 
Although SAH shows familial aggregation (Ronkainen et al., 1993; Ronkainen et 
al., 1999), the significance of the genetic component to SAH susceptibility appears 
to be low compared to acquired risk factors (Korja et al., 2010). Modifiable risk 
factors are estimated to account for six to seven, while genetic factors for only one 
of every ten SAHs (Ruigrok et al., 2001; van Gijn et al., 2007). 
4 Aiming to Tame Angiogenesis for Therapy 
Basic research tools, such as genetics, are invaluable in understanding essential dis-
ease risk. Furthermore, they provide a frame for corollary studies aiming to culmi-
nate in improved therapeutic approaches. Likewise, elucidation of physiological and 
pathophysiological processes advances therapy. The main focus of this thesis is cere-
brovascular pathologies and this chapter focuses on vascular biology in the healthy 
and in the sick. 
 
4.1 Functions of the Cardiovascular System  
The circulatory system of blood vessels ensures the distribution of oxygen, nutrients, 
hormones and even cells in large multicellular organisms such as humans. Gases 
and nutrient exchange occurs at the level of capillaries, which are 10-20 μm in di-
ameter. Blood vessel capillaries are found within 200 μm of any cell, with the excep-
tion of avascular tissues like cartilage, and the lens and cornea of the eye (Ambati et 
al., 2006).  
 
The luminal surface of all blood vessels is lined by a monolayer of endothelial cells 
(ECs) (Figure 2- page 22) (Risau, 1998).  The ECs have multiple functions; they 
regulate the blood flow via nitric oxide that acts on vascular smooth muscle cells 
(SMCs), they coordinate the traffic of cells and macromolecules between the blood 
and the interstitium, they alter their gene expression pattern to accommodate arte-
rial or venous functions (Hirashima et al., 2006), and they react to growth factors 
that stimulate the formation of new blood vessels. Even though ECs may appear 
similar in their ultrastructure, they do acquire tissue-specific phenotype, hence pro-
moting tissue-specific angiogenesis (Ruoslahti et al., 2000; Trepel et al., 2002). The 
basolateral side of ECs is lined with a basement membrane and a 50-100 nm thick 
extracellular matrix dominated by elastic fibers, forming the internal elastic lamina. 
They are further surrounded by mesenchymal mural cells, such as pericytes in capil-
laries and the smallest arterioles and vascular SMCs in arteries. Pericytes are in in-
timate contact with the ECs, promoting their survival and providing physical stabil-
ity against haemodynamic stress (Armulik et al., 2005; von Tell et al., 2006).  Vascu-
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lar SMCs form a contractile ring in the tunica media of the arteries by which they 
regulate blood pressure and flow. In most arteries, with the exception of the cere-
bral ones (Nyström, 1963; Stehbens, 1972; Ostergaard et al., 1987), the vascular 
SMC layer is encircled by the external elastic membrane. The outer most layer of 
arteries is the tunica adventitia, a connective tissue layer.  
 
4.2 Vasculogenesis and Angiogenesis 
The cardiovascular system is the first organ system to develop during embryogenesis. 
Hemangioblasts are the common precursors of both the hematopoietic and EC 
lineages. The primitive vascular plexus of the mammalian embryo and yolk sac form 
via the aggregation of angioblasts that are of hemangioblast origin (Coultas et al., 
2005). The formation of vascular network from de novo differentiated ECs is called 
vasculogenesis. The early vascular plexus expands by sprouting via migration and 
proliferation of ECs. This process, the formation of new blood vessels from pre-
exsisting vasculature is referred to as angiogenesis.  
 
The nascent vascular network remodels according to the tissues’ needs by pruning 
excess vessels and the ECs adopt an arterial, venous, or capillary phenotype (Swift et 
al., 2009). The process of angiogenesis is closely linked to organogenesis (Lammert 
et al., 2001; Matsumoto et al., 2001; Lammert et al., 2003; LeCouter et al., 2003; 
Yoshitomi et al., 2004). After organogenesis the vessel network strives to meet the 
demands of the developing organ by sprouting, splitting, intussusception (longitu-
dinal splitting- Figure 11), and circumferential enlargement (Djonov et al., 2000). 
 
 
 
Figure 11. Basic steps of intussusception I-IV (modified from (Kurz et al., 2003)). 
Furthermore, in pathological processes such as tumourigenesis, tumour cells may 
hijack the existing vasculature by growing alongside vessels, a phenomenon called 
cooption (Holash et al., 1999). Rarely tumours may gain their blood supply by grow-
ing into blood vessels and replacing their cells, what is referred to as “vascular mim-
icry” (Maniotis et al., 1999).  
 
4.3 Biology of Angiogenesis  
Physiological neovascularisation is uncommon in stable adult tissues, although hy-
pertrophy such as seen in skeletal muscle growth or fat accumulation, or processes 
like wound healing, do stimulate the formation of new blood vessels (Zimmermann 
et al., 2003; Carmeliet, 2005). The primary mechanism of neovascularisation in 
adult tissues is angiogenesis, but vasculogenesis has been suggested to occur as well 
(Aicher et al., 2005; Kopp et al., 2006). Imbalances in the growth of blood vessels 
contribute to numerous disorders. Aberrant angiogenesis is associated with disor-
ders such as proliferative retinal vasculopathies (Gariano et al., 2005), and insuffi-
cient angiogenesis can lead to tissue ischaemias (Schaper et al., 2003; Folkman, 
2007). Furthermore, pathological angiogenesis is necessary for tumour growth and 
facilitates the haematogenous spread of cancer (Carmeliet et al., 2000; Hillen et al., 
2007; Carmeliet et al., 2011; Weis et al., 2011). Hypoxic cells, inflammatory cells 
and tumour cells may release cytokines, such as vascular endothelial growth factors 
(VEGFs) or angiopoietin-2 (Ang2) that can induce angiogenesis (Carmeliet et al., 
2011).  
  
4.3.1 VEGFs and Their Receptors 
The mammalian VEGF gene family is composed of five dimeric glycoproteins: vas-
cular endothelial growth factor (VEGF or VEGF-A), VEGF-B, VEGF-C, VEGF-D 
and placenta growth factor (PlGF). VEGFs bind and activate their high-affinity 
VEGF-receptors (VEGFRs) tyrosine kinases and the neuropilins (NP) (Ferrara et al., 
2003; Tammela et al., 2005). Binding to VEGFRs, VEGFs induce receptor dimeri-
sation and autophosphorylation followed by activation of various intracellular 
downstream molecules. The intracellular signalling typically converges at mitogen 
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activated protein kinases and proteins activating the actin cytoskeleton, leading to 
cell proliferation, migration and survival (Olsson et al., 2006) . 
4.3.1.1 VEGF 
VEGF (also known as VEGF-A) was discovered as the first member of the VEGF 
gene family (Senger et al., 1983; Ferrara et al., 1989; Leung et al., 1989). By binding 
to and activating VEGFR-1, VEGFR-2 (de Vries et al., 1992; Quinn et al., 1993) or 
NP-1, NP-2 (Soker et al., 1998; Gluzman-Poltorak et al., 2000), VEGF induces EC 
proliferation, sprouting and migration (Ferrara et al., 2005; Olsson et al., 2006). 
Furthermore, by inducing anti-apoptotic proteins, VEGF contributes to EC survival 
(Benjamin et al., 1997; Gerber et al., 1998). Via VEGFR-2, VEGF leads to the dis-
integration of endothelial adherens junctions resulting in increased vascular perme-
ability (Senger et al., 1983; Bazzoni et al., 2004; Gavard et al., 2006), hence its 
original name; vascular permeability factor (VPF). Additionally, VEGF can cause 
vasodilatation by inducing endothelial nitric oxide synthesis to decrease vascular 
smooth muscle tone (Hood et al., 1998; Kroll et al., 1999). In hypoxia, VEGF RNA 
and protein is strongly induced via the hypoxia-inducible factor–regulated elements 
of its promoter (Pugh et al., 2003). VEGF is ubiquitously expressed and indispensa-
ble during embryonic development; embryos lacking a single allele die in utero 
(Carmeliet et al., 1996; Ferrara et al., 1996; Weinstein, 1999).  
4.3.1.2 VEGF-B 
VEGF-B binds to VEGFR-1 and NP-1, but its biological role is poorly characterised. 
Homozygous deletion of Vegfb leads to a minimal phenotype in mice (Bellomo et 
al., 2000; Aase et al., 2001). Interestingly, in transgenic rats, VEGF-B appears to be 
a heart specific vascular growth factor inducing coronary vessel growth without 
increased permeability or inflammation (Bry et al., 2010). 
4.3.1.3 VEGF-C and VEGF-D 
VEGF-C and VEGF-D are very similar in their structure. Their proteolytically proc-
essed forms bind to VEGFR-2 and/or VEGFR-3 (Joukov et al., 1996; Achen et al., 
1998). In mice, VEGF-C is expressed predominantly in the lymphatic vessels and in 
lymph nodes both during development (Kukk et al., 1996; Kärkkäinen et al., 2004) 
and in the adult organism (Lymboussaki et al., 1999). Via VEGFR-2, VEGF-C and 
VEGF-D can also increase vascular permeability (Veikkola et al., 2001; Saaristo et 
al., 2002). Complete absence of lymphatic vasculature is seen in mouse embryos 
after homozygous deletion of Vegfc (Kärkkäinen et al., 2004), but not Vegfd (Baldwin 
et al., 2005). 
4.3.1.4 PlGF 
Similarly to VEGF-B, PlGF binds to VEGFR-1 and NP-1. PlGF is potently arterio-
genic when administered locally (Pipp et al., 2003), however, its overexpression in 
the skin of transgenic mice leads to inflammation and increased permeability be-
sides marked angiogenesis (Luttun et al., 2002; Odorisio et al., 2002; Oura et al., 
2003). The mechanism of PlGF effects is likely mediated by the displacement of 
VEGF from VEGFR-1, making it available for VEGFR-2, and by the recruitment 
and stimulation of VEGFR-1 expressing inflammatory cells (Pipp et al., 2003; 
Fischer et al., 2007). Although Plgf gene targeted mice survive, they recover poorly 
from experimental myocardial infarction or hind limb ischaemia (Carmeliet et al., 
2001), pointing towards an important role for PlGF in angiogenesis under patho-
logical conditions. 
4.3.1.5 VEGFR-1 
VEGFR-1 is expressed by ECs and monocytes/macrophages (Zachary et al., 2001). 
VEGFR-1 is a poor mitogen for ECs, however, upon the formation of heterodimers 
with VEGFR-2, proliferation signalling is potentiated (Fong et al., 1995; Carmeliet 
et al., 2001; Huang et al., 2001). VEGFR-1 mediated angiogenesis and arteriogene-
sis are dependent on monocytes (Pipp et al., 2003). VEGFR-1 is indispensable for 
life, demonstrated by the embryonic lethality triggered by deletion of Vegfr1 in gene 
targeted mice (Fong et al., 1995; Fong et al., 1999). 
4.3.1.6 VEGFR-2 
VEGFR-2 is the primary receptor transducing VEGF signals, such as permeability in 
ECs, even though the affinity of VEGF for VEGFR-2 is almost 10 times weaker 
than for VEGFR-1 (Meyer et al., 1999; Wise et al., 1999; Gille et al., 2001). Also 
Vegfr2 gene targeted mice die during gestation (Shalaby et al., 1995; Gille et al., 
2001). VEGFR-2 expression is low, but constitutive in the adult blood vasculature 
(Partanen et al., 1999; Lee et al., 2007).  
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4.3.1.7 VEGFR-3 
During development, VEGFR-3 is expressed both by vascular and lymphatic ECs, 
but in the adult it is restricted to the lymphatic ECs and to the special fenestrated 
vessels of endocrine organs (Partanen et al., 2000). VEGFR-3 can form het-
erodimers with VEGFR-2 when stimulated by the mature forms of VEGF-C or 
VEGF-D (Dixelius et al., 2003; Olsson et al., 2006). As described for VEGFR-1 and 
VEGFR-2, VEGFR-3 is indispensable for mouse development (Dumont et al., 1998; 
Hamada et al., 2000). However, VEGFR-3 signalling appears not to be necessary for 
angiogenesis after organogenesis (Mäkinen et al., 2001). Both in humans and in 
mice, missense mutations in Vegfr3 have been linked to hereditary lymphoedema 
(Irrthum et al., 2000; Kärkkäinen et al., 2000; Kärkkäinen et al., 2001).  
4.3.1.8 Neuropilins 
NP-1 and NP-2 are transmembrane receptor glycoproteins without enzymatic activ-
ity (Takagi et al., 1991; Kolodkin et al., 1997). Their main ligands are class 3 sema-
phorins that mediate repulsive signals during neuronal axonal guidance (Kolodkin 
et al., 1997). However, they may also function as receptors for certain VEGFs, hence 
modulating angiogenesis and lymphangiogenesis (Carmeliet et al., 2005; Klagsbrun 
et al., 2005). NP-1 forms complexes with VEGFR-2, enhancing VEGF-VEGFR-2 
interactions (Soker et al., 2002). Likewise, NP-2 is a co-receptor that enhances 
VEGF-C/VEGF-D-VEGFR-3 interactions (Kärpänen et al., 2006). Np1 gene tar-
geted mice are embryonically lethal (Kawasaki et al., 1999), while Np2 homozygous 
mutants are viable, though they show lymphatic capillary hypoplasia (Yuan et al., 
2002).  
 
4.3.2 The Angiopoietins and their Tie Receptors 
The angiopoietin (Ang) growth factor family includes Ang1, Ang2, mouse Ang3, 
and its human orthologue Ang4 (Suri et al., 1996; Maisonpierre et al., 1997; 
Valenzuela et al., 1999). The Angs bind to Tie2, a receptor tyrosine kinase, which is 
expressed predominantly in the ECs and regulates vessel maturation and stability 
(Thurston, 2003; Brindle et al., 2006; Shim et al., 2007). Ang1 and Ang4 act as 
Tie2 agonists, however, Ang2 may act as an agonist or an antagonist, in a context 
dependent manner (Davis et al., 1996; Maisonpierre et al., 1997; Teichert-
Kuliszewska et al., 2001). When activated, Tie2 promotes EC survival and migration 
(Thurston, 2003; Brindle et al., 2006; Shim et al., 2007). The function of Tie1 is 
not yet fully understood, although it has a similar expressional pattern to Tie2 and 
may be activated by Ang1 and Ang4 in a Tie2 dependent manner (Saharinen et al., 
2005). Ang1 inhibits endothelial permeability in vitro (Wang et al., 2004; Gavard et 
al., 2008) and in vivo (Thurston et al., 2000), whereas Ang2 may lead to destabilised, 
leaky vessels in some conditions (Fiedler et al., 2004; Fiedler et al., 2006). Loss of 
Angpt1, Tie2 or Tie1 all lead to embryonic lethality (Puri et al., 1995; Sato et al., 
1995; Partanen et al., 1996). The Angpt2 null phenotype is viable, but defective in 
hyaloid blood vessel regression and lymphatic vessel maturation (Gale et al., 2002). 
 
4.4 Distinctive Angiogenic Features of the Central Nervous System 
4.4.1 Brain Angiogenesis During Development 
The blood supply in most organs develops by vasculogenesis, i.e. de novo vessel for-
mation during organogenesis. However, the brain obtains its blood supply purely by 
angiogenesis, i.e. by sprouting of preexisting pial vessels originating from the per-
ineural vascular plexus (Kurz et al., 1996; Kurz, 2000; Hogan et al., 2004; Ruiz de 
Almodovar et 
al., 2009; 
Liebner et al., 
2010). Hence 
the main ves-
sels supplying 
the brain re-
side on the 
surface of the 
brain, running 
between the 
lobes (Figure 
12).  
 
Figure 12. Cerebral arteries- inferior view  (modified from: www.angiocalc.com). 
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4.4.2 Neuronal Effects of Angiogenic Factors 
 
The vascular and neuronal systems 
show anatomical and physiological 
similarities (Figure 13) (Tam et al., 
2010). Increasing evidence shows 
that besides regulating vasculogene-
sis, angiogenesis and lymphangio-
genesis, the VEGF signalling system 
has a role in neurogenesis and mo-
toneuron survival (Oosthuyse et al., 
2001; Carmeliet et al., 2005; 
Greenberg et al., 2005; Carvalho et 
al., 2007). 
 
Figure 13. Anatomical paralells between the vascular and neuronal systems (modified from 
(Tam et al., 2010)). 
Neuronal cells and blood vessels already cross-talk during development, for exam-
ple, astrocyte growth provides a template for the growing blood vessels (Ruiz de 
Almodovar et al., 2009). Furthermore, an increasing amount of evidence shows that 
VEGF can support neural cells independently of its roles in vessels (Rosenstein et 
al., 2010). VEGF treatment promotes neuronal survival and neurite outgrowth in 
explant cultures (Silverman et al., 1999; Rosenstein et al., 2003). Additionally, 
VEGF is mitogenic for astroglia and Schwann cells in vitro and in vivo (Silverman et 
al., 1999; Sondell et al., 1999b, a; Schratzberger et al., 2000; Krum et al., 2002; 
Mani et al., 2005). Moreover, both glial cell types produce VEGF, to support neu-
ronal growth in vitro (Eddleston et al., 1993; Krum et al., 1998), hence it was long 
suspected that the neuronal effect of VEGF comes indirectly, transmitted by the 
glial cells. However, the observation that VEGF treatment increases neurite num-
ber, length, and size, as well as the size of the soma in primary CNS neuron cultures 
lacking glia, provided initial evidence that VEGF can directly affect neurons, inde-
pendently of glia (Rosenstein et al., 2003; Khaibullina et al., 2004). In addition, 
abnormal regulation of VEGF is implicated in neurodegenerative disorders 
(Oosthuyse et al., 2001; Lambrechts et al., 2003; Storkebaum et al., 2004). 
 
4.5 Anti-Angiogenic Therapy  
4.5.1 In Cancer 
Studying angiogenesis became a scientific discipline after the landmark paper by 
Judah Folkman (Folkman, 1971), formulating the hypothesis that beyond a few mm 
of size, tumours need their own vasculature to grow (Figure 14). Indeed, according 
to autopsy results, the human body often harbours small, avascular, clinically dor-
mant tumours (Nielsen et al., 1987; Black et al., 1993). Only a rather small propor-
tion (<0.5%) ever become clinically malignant (Feldman et al., 1986; Black et al., 
1993; Folkman et al., 2004). A possible explanation for these observations is that 
once exceeding a certain size, only those tumours that are able to switch to an an-
giogenic phenotype are able to maintain oxygen and nutrient supplies, thrive and 
metastasise (Folkman et al., 1991; Naumov et al., 2006). Hence this theory incepts 
the hope of possibly halting the malignant growth by inhibiting the tumour’s ability 
to recruit blood vessels (Folkman, 2002). Consequently, there was an urge in the 
scientific community to identify the supposed tumour angiogenesis factor (TAF). In 
1989 Ferrara and colleagues cloned the TAF and gave it its new name; VEGF 
(Ferrara et al., 1989).  
 
Figure 14. Schematic illustration of the theory about the tumour’s oxygen supply switching 
from diffusion to perfusion with the help of the tumour angiogenesis factor 
(TAF) (modified from (Folkman et al., 1971)). 
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Blood vessels of most tumours are poorly organised and leaky (Jain, 2005; Weis et 
al., 2005), as in malignant astrocytic brain tumours (Apuzzo et al., 1981; Anderson 
et al., 2008). This is likely due to the very high level of VEGF production (Weis et 
al., 2005, 2011). Anti-angiogenic therapy in model organisms has indeed decreased 
tumour vascularisation and growth, however, in some cases it simultaneously in-
creased tumour cell invasion (Keunen et al., 2011), and vessel cooption (Holash et 
al., 1999; Rubenstein et al., 2000).  
 
A significant advancement in anti-angiogenic therapy was achieved in February 
2004, when the US Food and Drug Administration (FDA) approved bevacizumab, a 
humanised anti-VEGF monoclonal antibody, for the treatment of metastatic colo-
rectal cancer in combination with 5-fluorouracil-based chemotherapy regimens 
(Hurwitz et al., 2004). Unfortunately, the treatment of most malignancies with anti-
angiogenic agents is ineffective or just briefly effective, hence limiting their clinical 
significance. One can theorise that the malignant process could likely be stopped by 
inhibiting the angiogenic switch. However, it seems that once a malignancy with 
angiogenic potentials has developed, anti-angiogenic therapy, especially as a mono-
therapy, is only rarely of clinical benefit (Bergers et al., 2008; Carmeliet et al., 2011). 
It is possible that starving a tumour of its blood supply is not a feasible approach to 
suppress cancer progression and alternatively, we may rather turn our focus towards 
normalisation of the tumour vasculature (Jain, 2005; Weis et al., 2011). 
 
4.5.2 In Neovascular Age-Related Macular Degeneration 
Anti-angiogenic therapy may be beneficial in diseases other than cancer that are 
characterised by excess neovascularisation. Such a disorder is neovascular (or wet) 
AMD. In 2004, the FDA approved pegaptinib, an aptamer that blocks the 165 
amino-acid isoform of VEGF, for the treatment of the wet form of AMD 
(Gragoudas et al., 2004) via intraocular injections. Furthermore, in 2006 the FDA 
approved ranibizumab, a monoclonal Ab fragment derived from bevacizumab, for 
wet AMD therapy (Rosenfeld et al., 2006). 
 
4.6 Towards Pro-Angiogenic Therapy 
There is an important and unmet clinical need for novel treatment strategies of 
common ischaemic conditions such as ischaemic heart disease (Zachary et al., 2011), 
critical limb ischaemia (Hastings et al., 2012) and cerebrovascular disorders.  
 
Angiogenic growth factors are promising candidates to correct perfusion by boosting 
collateral formation in ischaemic tissues. The angiogenic effects of VEGFs appear to 
be tissue specific, suggesting that the appropriate pro-angiogenic growth factor de-
pends on the tissue type. The biological usefulness of VEGFs in pro-angiogenic 
therapy have been demonstrated in a variety of tissues in model organisms (Isner, 
2002; Vajanto et al., 2002; Anisimov et al., 2009; Bry et al., 2010). However, no 
pro-angiogenic therapy is approved in humans to date, due to the difficulties in 
demonstrating clinically significant benefit (Simons, 2005). Suboptimal delivery 
strategies are an important part of this lack of success (Carmeliet, 2005), and ad-
vances in technology are likely to facilitate progress in this aspect as well.  
 
 
Aims of the Study 
The aim of the studies reported here was to gain further insights into cerebrovascu-
lar disorders and to move towards novel therapeutic approaches for these diseases 
(Figure 15).  
 
The specific aims were to: 
 
1. Elucidate to what extent common genetic variants contribute to the 
risk of developing IA tested by conducting two multi-national GWASs (I&II). 
2. Investigate whether IA and its epidemiological risk factor, high 
blood pressure, share a common genetic background tested by conducting an asso-
ciation study of IA risk loci with blood pressure in multiple large population based 
cohorts (n >210 000)  (III). 
3. Establish which vascular growth factor is the prime candidate for 
therapeutic vascularisation of the CNS by testing most known vascular growth fac-
tors in a rodent model (IV).  
 
 
Figure 15. Schematic representation of conducted studies. 
  
 
 
 
Materials and Methods 
1 Association Studies (I-III) 
A more detailed description of the study samples and methods used can be found in 
the original publications I-III and the references therein. 
 
1.1 Genome-wide Association Studies (I,II) 
1.1.1 Population samples in the GWASs 
Cohort characterisation and proper diagnosis is crucial for the success of GWA 
studies. The diagnosis of IA was made with CTA, MRA or DSA. IA rupture was 
defined by the identification of acute subarachnoid hemorrhage (via CT or MRI) 
from a proven aneurysm. Cases having at least one first-degree relative with intrac-
ranial aneurysm were considered familial, and other cases were considered sporadic. 
Patients with fusiform aneurysms were excluded. 
 
GWASs are often designed as two-staged, where discovery cohorts are utilised for 
true genome-wide screening and replication cohorts are used to gain further evi-
dence for the discovery phase results. Hence, the two GWASs presented here (I,II) 
are both constructed of a discovery- and a replication phase. Furthermore, utilising 
genetically diverse populations in the study makes it more probable that the identi-
fied locus (loci) holds significance for multiple populations (Gudbjartsson et al., 
2007).  
 
In the first GWAS (I) three independent cohorts from Finland (920 cases and 985 
controls), the Netherlands (781 cases and 6424 controls) and Japan (495 cases and 
676 controls) were recruited. Hence, for the number of IA cases, the Finnish cohort 
dominated. Only Japanese controls were screened for intracranial aneurysm, whilst 
Finnish and Dutch controls consisted of unscreened population cohorts. 
 In the second GWAS (II), to increase the power to detect additional loci of similar 
or smaller effect, two new European case cohorts (nTOTAL=2780) and five additional 
European control cohorts (nTOTAL=12 515) were ascertained. Additionally, we in-
creased the size of the Japanese cohort and added a new one (3111 cases and 1666 
controls in total). When combining all the old and new cohorts, we had nearly 
threefold the amount of cases than the original cohort and increased the power to 
detect variants even with modest effect sizes. When necessary, individuals were re-
moved based on genotyping quality, cryptic relatedness and due to being population 
outliers. 
 
1.1.2 Methods in the GWASs 
1.1.2.1 Genotyping and Imputation 
I 
Genome-wide genotyping was performed on Illumina platforms, such as the 
CNV370-Duo, HumanHap300 or HumanHap550 chips. SNPs shared across all 
platforms (n=314 125) were used in the analysis. Poorly performing genotypes were 
excluded at a SNP or individual base, by applying pre-specified criteria, which were 
met by 289 271 SNPs. Over 70 duplicates showed 99.91% genotype identity, con-
firming the genotyping quality. In the first GWAS (I), only directly genotyped auto-
somal SNPs were used.  
 
II 
Again, whole-genome genotyping for the discovery cohort was performed on Illu-
mina platforms. Replication genotyping was performed using Taqman (Applied 
Biosystems) or MassARRAY (Sequenom) assays, or multiplex PCR-based Invader 
assay (Third Wave Technologies Inc.).  
 
Imputation refers to the computed process of estimating non-genotyped genotypes 
by using known population allele frequencies across a haplotype. In other words, it 
means educated guessing of untyped SNP genotypes based on their neighbours, 
with the help of reference data. Imputation always carries uncertainty, and its accu-
racy varies greatly. We performed imputation analysis with the HapMap phase II 
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CEU reference panel using the IMPUTE v1 software, calculating posterior prob-
abilities and converting it to the most likely genotype, when it could be estimated 
with a 90% certainty. The association analysis was based on 831 532 SNPs (both 
genotyped and imputed) that passed the quality control (QC) filters in all cohorts. 
 
1.1.2.2 SNP Association Analysis 
I. 
To test each SNP for association with intracranial aneurysm, we assumed an addi-
tive model. We applied the Cochran-Armitage trend test for each cohort and the 
Mantel extension test for the combined cohorts. We calculated the per-allele and 
genotype-specific odds ratios and their 95% confidence intervals. Association with 
IA at a SNP was considered significant if it passed the conservative threshold of 
5x10-7, commonly applied at that time. For each chromosome segment showing 
significant association with IA, we investigated whether the association signal comes 
from a lone SNP (making false positive result more likely) or whether more than 
one SNP had an independent effect. Exactly 15 SNPs from the discovery cohort 
were carried on to seek their replication in the Japanese cohort. Genotypes were 
confirmed by two independent methods (Sequenom iPLEX and TaqMan platform 
(Applied Biosystems)). P values smaller than 0.05 were considered significant in the 
replication phase. For SNPs with the most significant P values we tested whether 
confounding variables such as rupture status, family history or gender, had an effect 
on the association results. Further, we calculated the cumulative effects of risk al-
leles at the identified susceptibility loci.  
 
II. 
The previous study had limited power to detect loci with genotypic relative risk 
<1.35, hence we increased cohort size and performed a new GWAS as follows: asso-
ciation with IA was tested for each QC–passed SNP using conditional and uncondi-
tional logistic regression for the discovery and replication cohorts, respectively. In 
the discovery cohort, we used the matched sub-cohort to guide correction for poten-
tial confounding due to population stratification and gender, and for the replica-
tion cohorts we adjusted for gender. A cohort-wise association analysis of the sub-
cohorts (such as the Finnish and other European cohorts) was performed, and re-
sults were combined using a fixed-effects model of meta-analysis. We evaluated the 
strength of association with intracranial aneurysm by a Bayesian approach, provid-
ing by the Bayes factor an alternative that compares the probabilities of the data 
under the alternative hypothesis of association versus the null hypothesis of no 
association. Further, we calculated the posterior probability of association (PPA) of 
the top loci (P<10-5). The PPA provides a probabilistic measure of evidence by in-
troducing the prior probability of association, π1. We uniformly assumed a π1 = 
1/10 000, for all SNPs analysed.  
 
1.1.3 Copy Number Variation Analysis in the GWAS cohorts 
1.1.3.1 Population samples  
 
A subset of the GWAS cohorts (I,II), 
with obtainable bead intensity data, was 
utilised for CNV analysis. Bead intensity 
data (Picture 5) was available for 2830 IA 
cases of Finnish (n=974), German 
(n=1056) and of Dutch (n=800) origins. 
Population matched controls were avail-
able for all cohorts (nTOTAL=7460) 
(Conrad et al., 2010; Casals et al., 2012). 
Picture 5. Example of bead intensity drop at the site of a deletion at 22q11. SNPs are repre-
sented by blue dots plotted for chromosomal location (x-axis) and intensity (y-axis). Red line 
shows average intensity. 
1.1.3.2 CNV Calling and Quality Control 
SNPs present on all three platforms (CNV370-Duo, HumanHap300 and Human-
Hap550) were utilised in CNV analysis, by pruning down all chips to consensus 
SNPs. To increase confidence of CNV detection, we used the merged output of 
three algorithms, namely:  PennCNV (Wang et al., 2007), QuantiSNP (Colella et 
al., 2007) and GNOSIS, the latter being an in-house script at Yale University, 
School of Medicine. PennCNV applies an integrated hidden Markov model, while 
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QuantiSNP is based on an objective Bayes hidden Markov model. GNOSIS uses a 
continuous distribution function to compare the intensity values with the HapMap 
data to infer copy-number changes. Stringent QC criteria were applied after CNV 
calling according to algorithms’ guidelines. We merged CNV predictions with 
CNVision, an in-house script at Yale University, School of Medicine. After merging 
CNV calls, as further QC, samples exceeding the number of average CNV 
call/sample with over 2 SD were excluded. Altogether 10% of the samples were 
excluded with QC. Annotation and downstream analysis was performed with the 
Plink v1.07 software (Purcell et al., 2007). For pathway analysis we used the gene 
relationships across implicated loci analysis tool (Raychaudhuri et al., 2009). All 
CNVs of interest were confirmed by q-PCR. 
 
1.1.3.3 Enriching for Dosage Sensitive Genes  
Certain genes are less likely to tolerate copy-number changes, hence CNVs in these 
genes tend to have phenotypic consequences. These genes are referred to as dosage 
sensitive genes. Evolutionarily dosage sensitive genes will be protected from copy-
number changes, hence CNVs will affect these genes rarely (Schuster-Bockler et al., 
2010). In order to increase the chance of finding biologically likely important CNVs 
in our dataset, we focused our analysis only on deletions that affect possibly dosage 
sensitive genes (Fujita et al., 2011). We constructed the list of possibly dosage sensi-
tive genes with the help of our population specific CNV cohorts (Conrad et al., 
2010; Casals et al., 2012). To define the possibly dosage sensitive genes, the follow-
ing was done: for computational purposes we combined overlapping isoforms of the 
approximately 20 000 RefSeq genes to form a single gene. Isoforms that did not 
overlap were left as duplicates. Genes that were affected by structural variations 
according to the Database of Genomic Variants (Iafrate et al., 2004) were all ex-
cluded from further analysis, excluding about 50% of all genes. Genes affected by 
100bp-1kb sized indels in DGV were excluded as well. Furthermore, all genes that 
were affected by at least one CNV in the control cohorts were excluded, leaving 
5771 genes for further analysis. We searched our CNV calls for rare events that are 
unique to cases and affect one of the 5771 genes not seen with CNV before, hence, 
possibly being dosage sensitive. 
 
1.2 Association Analysis of IA Risk Loci with Blood Pressure (III) 
1.2.1 Population Samples 
The cohorts are characterised in detail in the publication. Briefly, four Finnish 
population-based cohorts and a mixed-European cohort, not characterised for IA, 
were used in the study. We included participants with available blood pressure data, 
and excluded all on blood pressure medication or if blood pressure medication data 
were unavailable. Similar to GWAS, a multi-stage approach was applied, with a 
smaller discovery cohort (n=1581), followed by a larger Finnish replication cohort 
(n=8312) and an exceptionally large mixed-European second replication cohort 
(n>200 000) of The International Consortium for Blood Pressure Genome-Wide 
Association Studies (ICBP-GWAS).  
 
1.2.2 Methods of IA Risk Loci Association Analysis with BP 
1.2.2.1 IA Risk Loci 
The GWASs identified 5 loci with strong association (PPA>0.5) and a further 14 
loci with suggestive association (0.1<PPA<0.5) with IA (I,II and (Yasuno et al., 
2011)). These 19 loci (Table 6) were tested for association with blood pressure in 
this study.  
 
1.2.2.2 Genotyping and Imputation 
Finnish cohorts were genotyped using Illumina arrays: Illumina Infinium HD Hu-
man610-Quad BeadChip, Illumina HumanCNV370-Duo BeadChip, and Illumina 
Human670K custom BeadChip. For risk loci SNPs with no directly genotyped data 
available, we imputed genotypes with MACH using HapMap CEU from Phase II as 
the reference panel or with IMPUTEv2 using the 1000 Genomes pilot data CEU 
panel in combination with HapMap Phase 3 haplotypes, extended with Finnish 
specific HapMap Phase 3 haplotypes. 
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Table 6. IA risk loci.  
Representative SNPs of loci with PPA>0.5 (II) 
Locus SNP Gene Risk Allele Finnish P 
8q12.1 rs9298506 3’-SOX17 A 1.0E-05 
9p21.3 rs1333040 CDKN2A/B T 5.3E-08 
10q24.32 rs12413409 CNNM2 G 4.2E-02 
13q13.1 rs9315204 STARD13 T 1.7E-04 
18q11.2 rs11661542 RBBP8 C 2.3E-02 
Representative SNPs of loci with 0.1<PPA<0.5 (Yasuno et al., 2011) 
Locus SNP Gene Risk Allele Finnish P 
1p36.31 rs1876848 CAMTA1 G 1.3E-01 
1p22.2 rs1725390 BARHL2-ZNF644 A 1.4E-03 
1q21.3 rs905938 DCST2 T 6.7E-03 
2q33.1 rs787994 ANKRD44-SF3B1 T 2.9E-04 
4q31.23 rs6841581 upstream EDNRA G 4.0E-03 
5q23.2 rs335206 PRDM6 C 5.9E-03 
8p23.2 rs2045637 CSMD1 A 9.2E-05 
8q24.23 rs1554349 
FAM135B-
COL22A1 
A 2.3E-02 
11q22.2 rs2124216 YAP1-BIRC3 A 4.5E-04 
12p13.31 rs728342 TMEM16B G 4.8E-02 
12q22 rs6538595 FGD6 A 1.7E-02 
19q13.12 rs1688005 FXYD5 G 3.8E-02 
20p12.1 rs1132274 RRBP1 A 1.0E-02 
22q12.1 rs133885 MYO18B G 2.2E-01 
Risk alleles are IA risk alleles for the whole GWAS cohort (II and Yasuno et al., 2011) and are aligned 
to the forward strand of the reference genome. If a SNP is intergenic, Gene represents the nearest 
gene. Finnish P values are association results of the Finnish sub cohort in the GWASs (II and Yasuno 
et al., 2011). 
 
 
1.2.2.3 Association Analysis with BP and Meta-Analysis of Results 
We tested 41 SNPs from 19 independent loci (Table 6). Quantitative outcome vari-
ables were systolic blood pressure (SBP), diastolic blood pressure (DBP), mean arte-
rial pressure (MAP) and pulse pressure (PP). We tested all 19 loci in a discovery 
cohort, and those that showed suggestive association with any of the outcome vari-
ables were further tested for association in the replication cohorts. We performed 
association analyses with an additive genetic model with ProbABEL, and with 
SNPTESTv2, depending on the imputational software used. We adjusted the analy-
ses for age, gender, smoking habits, alcohol consumption, and BMI. We combined 
association results in a fixed effect meta-analysis with MetABEL, and with 
METAv1.2. The best result at 5q23.2 in PRDM6 was further tested for association 
in the ICBP-GWAS cohort of 200 000 individuals of European descent. In the 
ICBP-GWAS, association with SBP was tested by linear regression assuming an 
additive model and correcting for age, age-squared and BMI. To gain the per-allele 
effect size on blood pressure, we calculated the mean SBP for the three genotypic 
states for the SNPs tested at 5q23.2, by using Plink v1.07. Fine-mapping of the 
5q23.2 region was done by testing all 1000 Genome SNPs (MAF>1%) in the region. 
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2 Growth Factor Induced Angiogenesis in the Murine 
CNS (IV) 
2.1 Methods Used in Model Organism 
2.1.1 Generation of Adeno-Associated Virus Vectors and Intracranial Injections 
Recombinant adeno-associated virus (AAV) vectors were generated from plasmid 
vectors transfected into packaging cells, purified, quantified by q-PCR and tested in 
vitro for their transduction efficiencies and protein production.  
 
The AAV vectors were injected intracranially, targeting the septo-diencephalic and 
septo-striatal subcortex. The injection was carried out as transcranial injections to 
identical sites, guided by the cranial sutures on anaesthesised 6- to 7-week old fe-
male C57BL/6J mice. Four injections were performed per mouse, each delivering 2 
μl of the desired vascular growth factor or the control vector (human serum albu-
min-HSA). The vascular growth factor effect was evaluated two weeks after transduc-
tion. All experiments were done in triplicate. 
 
All mouse experiments were approved by the Provincial State Office of Southern 
Finland and carried out in accordance with the institutional guidelines.  
 
2.1.2 Immunohistochemistry 
Table 7 summarises the primary antibodies (Abs) used in this study, and the types 
or molecules that were detected with them. The unconjugated primary Abs were 
detected with the appropriate secondary Ab conjugates. 
 
 
 
 
 
 
Table 7. List of Primary Antibodies Used in the Study.  
Name of Primary Abs What it Detects 
anti-podocalyxin  endothelial cells 
anti-platelet endothelial cell adhesion molecule (anti-PECAM-1) endothelial cells 
anti-platelet derived growth factor receptor beta (anti-PDGFR-β) pericytes 
anti-α-smooth muscle actin (anti-SMA) smooth muscle cells 
anti-CD45  leukocytes 
anti-glial fibrillary acidic protein (anti-GFAP) astrocytes 
anti-neurofilament 200 neurons 
anti-fibrinogen  fibrin 
 
2.1.3 Imaging Modalities and Statistical Analysis 
2.1.3.1 Fluorescent Microscopy and Transmission Electron Microscopy 
Compound fluorescent microscopy or confocal microscopy was used in multichan-
nel scanning in frame mode to analyse fluorescently labelled samples with 10x and 
40x magnifications. Three-dimensional projections were digitally reconstructed 
from confocal z-stacks.  
 
For transmission electron microscopy, the brains were post-fixed in osmium tetrox-
ide and embedded in resin. Thin sections were stained with toluidine blue to search 
for the region of interest, and ultra-thin sections were cut and prepared from the 
specific region. Magnifications of 20 000- 100 000x were used. 
 
2.1.3.2 Morphological and Quantitative Statistical Analysis of Vessels 
The microvessel area was defined and quantified as the PECAM-1 or podocalyxin 
positive area from low-magnification confocal micrographs. PDGFR-β positive peri-
cyte-covered microvessel area was measured and compared with the PECAM-
1/podocalyxin positive area. Inflammatory cell numbers per injection site were 
counted from CD45 stained micrographs using low-magnification. The contrast of 
the images was adjusted using PhotoShop software (Adobe). For statistical analysis, 
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we used one-way ANOVA from PASW Statistics 19.0. P<0.05 was considered statis-
tically significant. 
 
2.1.3.3 Optical Projection Tomography with Lectin Staining 
This experiment was carried out to test for vessel leakiness in vivo after vascular 
growth factor injection. Unilateral growth factor injections were carried out accom-
panied by contralateral sham injections. Two weeks thereafter, blood vessels were 
stained with fluorescently labelled tomato lectin injected into the tail vein; the lectin 
was allowed to circulate for 5 minutes before sacrificing the animal. Lectin stains all 
exposed surfaces it comes into contact with. Hence, in the case of leaky vessels, the 
lectin will extravasate and label the surrounding tissue. The brain isolated from the 
skull was made transparent chemically, embedded in an agarose gel and mounted 
on a rotatory stage for viewing (Figure 16). 
 
 
 
 
Figure 16. Schematic model of OPT imaging (modified from (Sharpe, 2004)). 
Image Acquisition. Optical projection tomography (OPT), involving optical micros-
copy, is a relatively new method, which allows the capture of 360° images of trans-
parent objects of the size-range 1mm- 2cm (Sharpe et al., 2002). The brains were 
scanned stepwise at a 0.9° resulting in 400 images of projection data over a com-
plete revolution (Figure 16). Appropriate filters were applied to detect autofluores-
cence and fluorescent signals from the specific dyes. Image stacks and three-
dimensional volumetric representations were reconstructed from the raw data.  
 
2.1.3.4 Magnetic Resonance Imaging 
MRI was carried out in order to obtain further insight into the possible in vivo side-
effects of vascular growth factor treatment. Unilateral growth factor injections were 
carried out, accompanied by contralateral sham injections and analysed two weeks 
thereafter. T1-weighted sequences with and without contrast agent, T2-weighted and 
T2*-weighted sequences were obtained with a 4.7 T MRI scanner from the anaes-
thetised mice.  
 
 
 
 
Results and Discussion 
1 Common Genetic Susceptibility to IA (I,II) 
After candidate gene and linkage studies failed to identify variants strongly increas-
ing the risk of IA, a new approach was needed by scanning the whole genome in a 
hypothesis generating way, i.e., with GWAS.  
 
1.1 The First GWAS Identified Three IA Risk Loci at 2q33.1, 8q11.23-
q12.1 and 9p21.3 
The discovery phase, consisting of Finnish and Dutch cohorts aimed at identifying 
intervals harbouring SNPs that surpass the preset threshold of 5x10 -7 for association 
with IA (Wellcome-Trust-Case-Control-Consortium, 2007). The replication of asso-
ciation was tested in the Japanese cohort, with and expected significance of P<0.05 
for a positive result (Figure 17). After carefully matching cases and controls, and 
meticulous QC passed by 289 271 SNPs, the genomic inflation factor was 1.043 for 
the Finnish and 1.136 for the Dutch cohort. The genomic inflation factor of the 
combined cohort was 1.114 combined, indicating successful matching (Clayton et 
al., 2005).  
 
In the discovery stage for the European cohorts, 4 regions harboured at least one 
SNP surpassing the 5x10-7 significance threshold, and 16 SNPs showed association 
of P<10-6. The strength of the association came both from the Finnish and the 
Dutch cohorts. This number is greater than what is expected under the null hy-
pothesis of no association with IA. Fifteen out of the 16 SNPs resided in four inter-
vals, namely: 1q42.3, 2q33.1, 8q11.23–q12.1 and 9p21.3. The strongest association 
was observed at 9p21.3. This locus has already been shown to associate with IA and 
AAA (Helgadottir et al., 2008), and the same LD block was shown to be associated 
with myocardial infarction (Helgadottir et al., 2007; McPherson et al., 2007; 
Wellcome-Trust-Case-Control-Consortium, 2007). The loci 1q42.3, 2q33.1 and 
8q11.23–q12.1 were novel and have not previously been shown to be in association 
with IA or any other traits. 
 
 
 
Figure 17. Workflow summary of the first GWAS (I). 
To test whether these four loci are significant in a non-European population as well, 
we attempted replication in a Japanese cohort by genotyping the 15 SNPs. Of the 15 
SNPs, 8 replicated the significant association with IA, including SNPs from 2q33.1, 
8q11.23–q12.1 and 9p21.3. After combining the result from the discovery and 
replication cohorts, the strongest association with IA was observed at 8q11.23 and 
at 9p21.3. The loci with representative SNPs are summarised in Table 8. 
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Table 8. Representative SNPs of association peaks from the first GWAS (I).  
Locus SNP P 
2q33.1 rs700651 4.4E-08 
8q11.23 rs10958409 1.4E-10 
9p21.3 rs1333040 1.4E-10 
P-values are results from the combined discovery and replica-
tion cohorts. 
 
1.1.1 The Genes at and Nearby 2q33.1, 8q11.23–q12.1 and 9p21.3 
The association signal at 2q33.1 lies within a large block of LD in the European 
cohorts, but in Asian subjects, it is divided into two smaller LD blocks with the 
association confined to SNPs in the more telomeric block (198.2–198.5 Mb). The 
two most strongly associated SNPs lie in introns of adjacent genes, BOLL and 
PLCL1. PLCL1 may be of interest due to its significant homology to phospholipase 
C, involved in the VEGFR-2 signalling pathways (Shibuya, 2006), which are impli-
cated in central nervous system angiogenesis. 
 
At 8q11.23-q12.1, the two strongest signals (rs10958409 and rs9298506) in the 
discovery cohort are 110 kb apart and seem to be independent risk alleles, with no 
LD between them. The Japanese cohort replicated association only at rs10958409. 
Further studies are necessary to determine whether the association signal at 
rs9298506 was a true finding. The 8q11.23-q12.1 interval contains a single gene, 
SOX17, between the two European association peaks. Sox17 appears to have an 
important role in endothelial cell formation and maintenance (Matsui et al., 2006; 
Kim et al., 2007; Sakamoto et al., 2007).  
 
The most strongly associated SNP at 9p21.3 was rs1333040, from the region that 
previously showed association with IA and multiple other vascular diseases 
(McPherson et al., 2007; Wellcome-Trust-Case-Control-Consortium, 2007; 
Helgadottir et al., 2008) (Figure 10- page 53). Adjacent SNPs that are associated 
with type 2 diabetes mellitus (Saxena et al., 2007; Scott et al., 2007; Zeggini et al., 
2007) showed no significant association with IA. The strongest association signal is 
located between genes CDKN2A and CDKN2B, encoding cyclin-dependent kinase 
inhibitors. Later studies in model animals suggested the mechanism of this locus 
being excessive proliferation and diminished senescence in vascular SMCs via modi-
fied expressional levels of CDKN2A and CDKN2B (Visel et al., 2010).  
 
1.2 The Second GWAS Confirmed 8q12.1 and 9p21.3 and Identified 
Three New Loci 
To increase statistical power to detect susceptibility loci with smaller effects, the 
discovery cohort was enlarged with further European cases and controls (Figure 18). 
 
The strength of the association was measured by the PPA, calculated through the 
Bayes factor that provides a probabilistic measure of the evidence of association 
(Wakefield, 2007; Stephens et al., 2009). To further increase power, we imputed 
not genotyped SNPs using HapMap phase II CEU (Frazer et al., 2007) as reference 
panel, after which 831 532 SNPs passed QC. After performing association analysis, 
three regions showed very high PPAs (>0.995) and two additional regions showed 
high PPAs (>0.5). These results confirmed strong association with IA at 8q11.23–
q12.1 and 9p21.3, however, the 2q33.1 locus remained suggestive in this second 
study. The strongest signal at 2q33.1 in the first GWAS came from the Finnish 
cohort. The relative contribution of the Finns decreased in the second GWAS, 
whilst the locus simultaneously lost significance. This suggests that the 2q33.1 is 
predominantly a Finnish specific risk locus, although  further studies are needed to 
confirm this. The three newly identified loci were at 10q24.32, 13q13.1 and 
18q11.2 (Table 9). Furthermore, these new results confirmed the presence of two 
independent loci at 8q11.23–q12.1, as suspected in the previous study. Thus, the 
five chromosomal regions were comprised of six independent association signals. 
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Figure 18. Workflow summary of the second GWAS (II). 
 
We sought replication in two Japanese cohorts by genotyping 1-4 top SNPs from 
each independent signal. The replication was considered successful if the Bayes 
factor increased the odds of association more than tenfold with the replication data. 
Five out of the six candidate loci replicated, with only 8q11.23 failing replication. 
After combining the discovery and replication results with a fixed-effects model, all 
five loci surpassed the conventional threshold for genome-wide significance 
(P<5×10−8) (Table 9). The 9p21.3 locus showed a 1010 times stronger association 
with IA compared with the other loci. 
 
 
Table 9. Top SNPs of association peaks from the second GWAS (II).  
Locus SNP P 
8q12.1 rs9298506 1.3E-12 
9p21.3 rs1333040 1.5E-22 
10q24.32 rs12413409 1.2E-09 
13q13.1 rs9315204 2.5E-09 
18q11.2 rs11661542 1.1E-12 
P-values are results from the combined discovery 
and replication cohorts. 
 
1.2.1 The Genes at and Nearby 10q24.32, 13q13.1 and 18q11.2 
Among the newly identified loci, the strongest association was at 18q11.2, within an 
extended LD interval harbouring a single gene, RBBP8. The protein encoded by 
RBBP8 is involved in cell cycle progression via BRCA1 (Yun et al., 2009). The sec-
ond strongest new signal came from the associations at 10q24.32, residing in the 
first intron of CNNM2, with a role in magnesium homeostasis (Stuiver et al., 2011). 
The third new locus was at 13q13.1 in the intron 7 of STARD13. The overexpres-
sion of the STARD13 protein leads to the suppression of cell proliferation (Leung 
et al., 2005). 
 
1.3 The Five Loci Together Explain Only Little of the Familial Risk 
When assuming a fourfold increase of IA risk among siblings (Schievink, 1997; 
Cannon Albright et al., 2003) and furthermore that the SNPs increase disease risk 
in an additive fashion, we estimate that together the five IA risk loci account for 3.5-
5.2% of the familial risk of IA.  
 
1.4 No Top Loci Associated with Gender, Family History or Age 
When trying to dissect the mechanism of the risk loci, we examined whether any of 
them show independent association to known risk factors, such as gender, family 
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history of IA and age. The results showed no significant independent contribution 
to risk by any of these factors. Unfortunately BP measurements and data on smok-
ing habits were not available from most cohorts.  
 
1.5 No Loci Associated with SAH 
Although biologically it is a fascinating question why aneurysms form, the most 
clinically relevant question is why they rupture. We tested whether any of the iden-
tified risk loci independently increase the risk of rupture. However, we found no 
significant contribution. Currently there is no known common risk locus of SAH.  
 
1.6 No Association within Previously Identified Linkage Intervals 
A tempting hypothesis is that rare, strongly penetrant mutations of a gene cause 
Mendelian forms of the disease, and less penetrant mutations of the same gene may 
contribute to population risk. Identifying mutations in a gene by two fundamentally 
different approaches, such as linkage and association, would strongly increase the 
likelihood of the genes’ true involvement in the diseases. Hence, we examined if any 
of the identified common IA risk loci reside in previously described linkage inter-
vals (Table 4- page 48-50). Consistent with GWASs in other traits, no association 
was seen with common variants at regions identified in familial linkage studies. 
 
1.7 CNVs in IA 
It is hypothesised that part of the missing heritability might be explained by rare 
structural and sequence variants. It might be due to a few variants with major effects 
or a vast number of rare variants all with individually modest effect size. The vast 
number of CNVs in apparently healthy individuals seems to confer that most CNVs 
are not disease causing per se. However, large (>500kb) CNVs affecting multiple 
genes are likely to have phenotypic consequences (Pietiläinen et al., 2011).  
 
Since common susceptibility loci account for only a minority of the genetic risk to 
IA, as is commonly seen with most complex disorders (Visscher et al., 2012), we 
examined whether rare variants, such as CNVs could explain some proportion of 
the putative hidden heritability. We found multiple rare, case-specific variants that 
delete or severely disrupt genes. Altogether 111 likely dosage sensitive genes were 
affected by these events. Most of these events were seen once, i.e. unique events. A 
few recurrent events were observed, affecting the genes SMARCA2 and TRAM1L1. 
Unfortunately, deep resequencing of these genes in over 90 cases did not reveal 
further mutations in the genes. At the time of the analysis, there were no further IA 
cohorts available to replicate their involvement in IA. 
 
1.7.1 Rare and Common Variants Affect the Same Pathways 
Although no CNVs were seen in the association regions, interestingly, some of the 
unique deletions affected the same pathways as did genes at GWAS loci. The two 
pathway axes that were hit by both common (GWAS) and rare (unique CNV) 
events are the CDKN2B-CDKN2A-E2F1-PMAIP1 axis effecting vascular SMC prolif-
eration and survival (Visel et al., 2010) and the STARD13-ITSN1-SRGAP2 axis point-
ing towards the possible involvement of the Rho GTPase cycle (Leung et al., 2005). 
Confirmation of their role warrants further studies. 
 
1.8 Possible Mechanism of IA Formation Based on GWAS Results 
The strongest common risk locus of IA is 9p21.3, a general vascular risk locus. 
Based on model animal studies it is suspected to effect via excessive proliferation 
and decreased survival of vascular SMC (Visel et al., 2010). The genes within the 
other association regions appear to be involved in progenitor cell–mediated vascular 
development and/or repair (Matsui et al., 2006; Kim et al., 2007; Sakamoto et al., 
2007). These findings point towards IA being part of a generalised vasculopathy 
prone to intracranial manifestation, rather than a disease of its own.  
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2 Suggestive IA Risk Locus is Associated with High 
Blood Pressure (III) 
The two GWASs identified 5 loci strongly associated with IA and further loci with 
suggestive association (Table 6- page 73). However, they could not provide evidence 
of supposed mechanisms of how these loci contribute to disease risk. The purpose 
of this study was to test in multiple independent, population based cohorts whether 
any of the IA risk loci show association with BP, an epidemiological risk factor of 
IA. The study design was three staged: the positive results from the discovery cohort 
(n=1581) were tested first in three further Finnish population-based cohorts 
(n=8312) and then tried for a second replication in a mixed European cohort 
(n>200 000). 
 
2.1 IA Risk Loci Association Analysis with BP 
Exactly 41 SNPs from 19 independent IA loci were tested in the discovery cohort 
for association with blood pressure, adjusted for age and gender. We observed ten-
dency of association at 2q33.1 with DBP and with MAP, at 4q31.23 and 19q13.12 
with DBP, and at 5q23.2 with SBP, DBP, and MAP. We did not detect association 
with PP.  
 
To analyse the independence of the association signals observed, we tested all SNPs 
from the 19 loci adjusting for further BP risk factors, such as smoking habits, alco-
hol consumption, and BMI. After adjusting for these factors, the strength of the 
association with DBP decreased at 4q31.23 and 19q13.12. At the 2q33.1 locus, 
after adjusting for the above mentioned factors, the strength of the association in-
creased marginally both with DBP and MAP. After adjusting the analysis for smok-
ing habits, alcohol consumption and BMI, the strength of association increased 
with SBP, DBP, and MAP substantially at 5q23.2, with all three SNPs tested 
(rs570682, rs2287696, rs335206). At all three 5q23.2 SNPs, the risk allele of high 
blood pressure was the same as for IA. 
 
In the three Finnish follow-up cohorts, the significant association with DBP and 
MAP, at both 2q33.1 and at 5q23.2, failed to replicate. However, all tested SNPs at 
5q23.2 showed strong association with SBP in all Finnish replication cohorts (PFIN= 
3.01x10-5). Furthermore, the 5q23.2 SNPs showed strong association with SBP in 
the mixed European cohort of ICBP-GWAS (n>200 000) (Ehret et al., 2011). When 
combining the results from all cohorts in a fixed-effect meta-analysis, the strongest 
association was observable at rs2287696 (P=8.13x10-7). The effect size of the locus 
on SBP is small, which is typical for all common risk loci of BP (Ehret et al., 2011), 
and of most complex diseases. In this study, participants homozygous for the risk 
allele, “A” in the case of rs2287696, had on average 1.3 Hgmm higher SBP com-
pared to those who were homozygous for the protective allele, and 0.9 Hgmm 
higher than those with the heterozygous genotype. 
2.2 Fine-Mapping the 5q23.2 Region 
 
 
Figure 19. LD structure of the 5q23.2 locus with –ln(P) projected above them. The SNPs 
showing the strongest association with BP reside in the second intron of 
PRDM6 (encircled with green). 
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IA risk loci SNPs tested at 5q23.2 reside in the intronic regions of PRDM6. To fur-
ther explore the associated region we examined all 1000 Genomes variants (The-
1000-Genomes-Project-Consortium, 2010) in and around PRDM6 in the four Fin-
nish cohorts. The strongest association was observed in the second intron with 
rs163189, near rs570682 and rs2287696. The most significantly associated SNPs 
clustered within a 4.7kb region (Figure 19), surrounding a transcription factor bind-
ing site.  
 
2.3 Possible Mechanism of IA and High SBP Risk 
PRDM6 encodes an epigenetic modulator of transcription with roles in ECs (Wu et 
al., 2008) and vascular SMCs (Davis et al., 2006), where it is highly expressed. 
When active, PRDM6 inhibits differentiation and promotes proliferation of vascu-
lar SMCs (Davis et al., 2006), hence, intriguingly, having a very similar effect as is 
supposed for the strongest common IA risk locus at 9p21.3 (Visel et al., 2010).  
 
2.4 Causality or Pleiotropy? 
Based on these results, it is not possible to tell whether the identified risk variant at 
5q23.2 increases the risk of developing IA as a consequence of elevated SBP or if 
the variant modifies the vessel wall in a way that elevates SBP and as a pleiotropic 
effect concurrently increases IA risk (Figure 20). Likely, the mechanical effect of 
elevated SBP on the vessel wall exacerbates IA formation. To further dissect the 
question of causality vs. pleiotropy, one would need to study a cohort characterised 
both for IA and blood pressure. To the best of our knowledge, such a large-scale 
cohort currently does not exist.  
 
 Figure 20. Causality vs. pleiotropy as possible explanations for the overlapping association 
with IA and SBP at 5q23.2. 
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3 CNS Angiogenesis in a Model Organism (IV) 
3.1 Therapeutic Brain Revascularisation 
Different types of pathologies, such as CCH or complex IA, may necessitate revascu-
larisation in the CNS. Current CNS revascularisation treatment strategies are pre-
dominantly surgical and focus on re-opening or bypassing the occluded or ill vessel 
segment. The surgical risks and the anaesthesiological risks of such procedures may 
be prohibitively high. Furthermore, in the case of chronically compromised cerebral 
blood flow, abrupt correction carries risks. There is a clinical demand for a low risk, 
gradual revascularisation procedure. 
 
In order to address this, we systematically screened, for the first time, the angiogenic 
potentials of most known vascular growth factors, in the murine CNS. The aim was 
to identify the vascular growth factor most suitable for therapeutic brain revasculari-
sation.  
 
3.2 PlGF Promotes the Formation of Arterialised Microvessels 
3.2.1 Significant Increase of Microvessel Density 
AAV9s encoding the human vascular growth factors were delivered to the septo-
diencephalic and septo-striatal subcortex of the murine brain by four separate injec-
tions. Two weeks following the injection, we observed that PlGF, VEGF and the 
short, activated form of VEGF-C (VEGF-CΔNΔC) had stimulated a comparable 
increase in the vascular area, as quantified by both podocalyxin and PECAM-1 im-
munofluorescence (Figure 21A and B). However, VEGF and VEGF-CΔNΔC pro-
moted the formation of hemangioma-like glomeruloid structures (Figure 21C and 
F), comprised of likely leaky, dysfunctional vessels. Hemangiomas were not observed 
in brains expressing the other factors. In contrast, PlGF promoted the formation of 
organised microvessels (Figure 21D). VEGF-B did not promote angiogenesis (Figure 
21A,B and G). As seen from the control (HSA) injected brain, the injection itself 
did not provoke a significant angiogenic response (Figure 21A,B,E and H). 
 
In summary- PlGF was the only vascular growth factor that strongly promoted an-
giogenesis without hemangioma formation. 
Figure 21. Effects of 
vascular growth factor gene 
transduction on the murine 
brain vasculature. Immu-
nostaining of the targeted 
brain regions two weeks after 
transduction. Quantifications 
of PECAM-1 (A) and podoca-
lyxin (B) positive areas. 
**P<0.01 and ***P<0.001, 
when compared to HSA con-
trol. Arrowheads point to 
hemangiomas (C,F). Arrows 
point out needle path 
(D,E,G,H). Scale bar: 200 μm. 
3.2.2 PlGF Induced Mi-
crovessels Arterialise 
Blood vessels formed in 
response to PlGF dis-
played hallmarks of ma-
ture vessels. Newly formed 
microvessels in PlGF 
transduced brains were 
covered by PDGFR-β 
positive pericytes. Fur-
thermore, the number of 
arterialised microvessels 
increased significantly 
after PlGF gene transduc-
tions. The PlGF treat-
ment-induced small arter-
ies were surrounded by a 
continuous layer of SMA positive smooth muscle cells.  
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3.3 PlGF Induced Angiogenesis Does Not Incite Significant Side Ef-
fects 
3.3.1 No Strong Inflammation 
VEGF family growth factors may promote inflammation, an unwanted and poten-
tially life-threatening side-effect in the CNS. Furthermore, inflammation can indi-
rectly contribute to angiogenesis, confounding the direct 
pro-angiogenic effect of the vascular growth factor. When 
evaluating the extent of inflammatory cell recruitment from 
the blood circulation upon vascular growth factor expres-
sion, we observed that human VEGF and VEGF-CΔNΔC 
potently recruited CD45 positive leukocytes, whereas nei-
ther human nor mouse PlGF significantly increased in-
flammatory cell numbers in the injection area, when com-
pared to the control (Figure 22). However, as expected, 
human PlGF recruited somewhat more inflammatory cells 
in the murine CNS than the murine PlGF. The difference, 
though, was insignificant. Further experiments indicated 
that the angiogenic effect of PlGF was not due to the in-
flammation it evoked.  
Figure 22. Inflammatory effects of vascular growth factor 
expression. Quantitative analysis of inflammation by CD45 positive 
cell count per injection site (A).  ***P<0.001, when compared to HSA 
control. B,C: Immunostaining for CD45 positive cells (red). Vascular 
counterstaining for podocalyxin (green). Scale bar: 50 μm. 
3.3.2 No Marked Gliosis or Neuronal Rearrangement  
Tissue damage induced proliferation of astrocytes is referred to as gliosis, resulting 
in scar formation in the CNS. Gliotic scars have the potential to provoke epileptic 
activity, an undesired side-effect of vascular growth factor treatment. To test 
whether the vascular growth factors promote gliosis, we examined the astrocyte- and 
neuronal architecture by immunohistochemical staining, two weeks after gene trans-
fer. We did not observe marked gliosis after PlGF treatment and the neuronal ar-
chitecture was not visibly affected when compared to the HSA control. In contrast, 
the VEGF or VEGF-CΔNΔC gene transductions were associated with substantial 
gliosis, and distortion of neuronal structures. Thus, in summary, VEGF and VEGF-
CΔNΔC induced hemangioma formation, glial scars and a mispatterned neuronal 
architecture, which are all undesired side effects of pro-angiogenic therapy. 
 
3.3.3 BBB is Intact and Functional  
Vascular growth factor treatment may interfere with the BBB without further obvi-
ous side-effects. Thus, we examined BBB anatomy by electron microscopy and its 
functionality by in vivo extravasation assays. Electron micrograms showed that capil-
laries formed upon PlGF treatment displayed mature basal laminae, associations 
with mural cells and contacts with astrocyte foot processes, i.e. anatomically the 
BBB appeared to be intact. 
 
To further, functionally investigate the BBB of newly formed microvessels, we tested 
for plasma leakage by staining for extravasated fibrinogen. Fibrinogen, once extrava-
sated, gets deposited as fibrin in the perivascular tissues. We observed fibrin outside 
of the vessels in the VEGF and VEGF-CΔNΔC treated brains, indicating substantial 
vessel leakage. In contrast, no significant leakage was observed after PlGF treatment.  
 
To further test BBB functional integrity in vivo, we stained for plasma extravasation 
by fluorescently labeled tomato lectin and visualised the results using OPT. After 
VEGF gene transfer we observed strong extravasation at the site of the VEGF-
induced angiomas. Importantly, the dense capillary network formed upon PlGF 
treatment did not show signs of plasma extravasation.  
 
3.3.4 Intact In Vivo Anatomy 
We compared the in vivo effects of VEGF, VEGF-B (as negative control) and PlGF 
treatments by MRI, two weeks after right-sided vascular growth factor and left-sided 
sham injections. After VEGF treatment, a major distortion of anatomical structures 
including a brain midline shift was observed in the T1 sequence. Gadolinium-based 
contrast agent revealed the breakdown of the BBB in a strikingly wide region 
around the VEGF transduction site and the T2 series demonstrated severe oedema 
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over the majority of the corresponding hemisphere. The T2* series visualised a large 
area of microhaemorrhages after VEGF treatment. On the contrary, after PlGF and 
VEGF-B gene transfers, the en gross anatomy appeared to be normal, without signifi-
cant oedema or enhancement, indicative of an intact BBB.  
 
3.4 PlGF Is the Prime Candidate Vascular Growth Factor for CNS 
Revascularisation 
Taken together, these results indicate that both mouse and human PlGF induce the 
formation of mature and arterialised vessels comprising an intact BBB, with mini-
mal inflammation, gliosis and vessel leakage. 
Present State and Future Perspec-
tive 
1 Overhauling the Status Quo of IA 
1.1 Is IA a Disease of its Own? Is IA Genetic? 
A few decades ago we assumed IAs to be congenital, however, further studies 
showed that they form de novo during one’s lifetime (Rinkel et al., 1998). A few 
years ago we assumed IA being (1) a distinct disease with a (2) significant genetic 
component to its risk. In this thesis, I summarise the latest results on the subject, 
showing that common genetic risk factors do not appear to explain a significant 
proportion to the risk of IA. Furthermore, the strongest common risk locus of IA is 
9p21.3, a common cardiovascular risk locus. Based on these results, I suggest that 
we start to reshape our thinking about sporadic IA and consider it as (1) an intrac-
ranial manifestation of a generalised vasculopathy, as supported by epidemiological 
evidence (Rinkel et al., 1998; Huttunen et al., 2011; Vlak et al., 2011; Pyysalo et al., 
2012). Additionally, sporadic IA, as most complex diseases, appears to lack a genetic 
contribution that would guide us in day-to-day clinical decision-making (2). 
 
 
2 Quo Vadis IA Research? 
Some potential future projects that I outline here represent a logical continuation of 
the research results presented in this thesis, others are signalling the old-new era of 
genetics: the Mendelian boom No 2.  
 
2.1 Search for Finnish Specific IA Loci 
Although the two GWASs succeeded in describing most of the common IA risk loci 
that hold significance in multiple nations, there are likely population specific loci in 
isolates, such as the Finns. As mentioned earlier, the 2q33.1 locus appeared to be a 
predominantly Finnish-specific IA locus. Furthermore, the Finnish population is 
broken into multiple subpopulations, like the Kuusamo isolate. It is possible that 
the common genetic risk in these isolates is carried only by a few, higher impact 
variants. These variants may have the traditional value of highlighting disease-
associated pathways. Studies aiming to answer these questions are under way by our 
collaborators at Kuopio Neurosurgery. Furthermore, Finnish specific studies on 
SAH genetics may bring us closer to understanding the background of the higher-
than-average rupture rate of IA in Finland. 
 
2.2 Mendelian Boom No 2 and Beyond 
The costs of whole-exome and whole-genome sequencing have come down expo-
nentially. This facilitates the sequencing of families exhibiting the rare, Mendelian 
forms of IA and it is very possible that causative variants will be identified from the 
linkage regions. These studies are potentially pending, yet since most humans are 
expected to carry approximately 20 completely inactivated genes in their genome 
(MacArthur et al., 2012), further proof of causality will be required from, for exam-
ple, functional studies. It is likely that these mutations are family-specific, and their 
global value will lie in highlighting disease related pathways. It should be noted, that 
in a Mendelian form of thoracic AAA complicated with IA, whole-exome sequenc-
ing has already yielded results (Regalado et al., 2011). This, revisiting family re-
search, is what I refer to as Mendelian boom No 2.  
 
Furthermore, sequencing studies are accompanied by expressional assays with a 
growing frequency and will be likely followed-up by works investigating the role of 
methylation and imprinting, for example. 
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2.3 Genetic Diagnostics in Sporadic IA is Unlikely 
Currently, only a few biologically plausible IA genes are known, such as ENDRA 
(Yasuno et al., 2011), SMAD3 (Regalado et al., 2011) or PRDM6 (III), and a handful 
of associated loci. Even if these gain functional confirmation and the list of genes 
grows considerably, a clinically significant genetic test evolving for sporadic IA is 
unlikely, particularly in the near future. 
 
2.4 Shaping Future Therapies 
As mentioned previously, since the contributions of the individual risk loci are 
small, likely no therapy can be based directly on them. However, the improved un-
derstanding of the diseases and their genetic background, may aid public health 
decisions. 
 
2.5 Further Epidemiological Studies are Needed 
The number of IA is the same in Finland, Japan and Northern Sweden as the rest of 
the world, however, IAs appear to be more rupture-prone in these regions (Ohkuma 
et al., 2002; Sivenius et al., 2004; Stegmayr et al., 2004). Since the genetic risk does 
not have a major contribution to SAH (Ruigrok et al., 2001; van Gijn et al., 2007; 
Korja et al., 2010), one can speculate that the higher-than-average rupture rate is 
due to environmental- and life-style related factors. Such a risk factor in Finland 
may be the population’s infamous alcohol consumption with a tendency towards 
binge drinking (Popova et al., 2007) or perhaps the worldwide highest per capita 
coffee consumption is to blame (Argano et al., 2012; Wikipedia, 2012). Likewise, 
the incidence of smoking in Japan is notably high (Avila-Tang et al., 2009). In 
model organisms by environmental manipulation these questions may be teased 
apart. However, the approach to decipher this puzzle in human populations is more 
perplexing. Nevertheless, life has created circumstances that highly mimic the ideal, 
laboratory settings (Table 10). In experimental genetics the real-life equivalents of 
environmental manipulation are migrant- and adaptation studies.  
 
Studying the SAH rates of Finnish and Japanese emigrants around the world, or of 
foreign  immigrants to Finland and Japan, could provide further evidence about the 
aetiology of the higher-than-average IA rupture rates (Marmot et al., 1984). Indeed, 
first generational Finns in Sweden were shown to have a higher risk of SAH than 
the general population (Khan et al., 2004). However, these results are limited by the 
facts that first generational migrants tend to keep the habits of their original coun-
try (Kagan et al., 1980). Furthermore, Japanese Americans are more likely to suffer 
from SAH than the general population, although SAH showed correlation with 
smoking (Klatsky et al., 2005).  
Table 10. Naturally occurring equivalents of experimental situations 
(modified from (Crawford, 2006)).  
Experimental Genetics Observational Genetics 
Saturation mutagenesis Mutation screening near nuclear disasters 
Gene knockouts Autosomal recessive diseases 
Inbred organisms Populations with low numbers 
Clonal populations Twin Studies 
Environmental manipulation Migrant studies/Adoption studies 
Random mating experiments Family studies 
Enormous pedigrees by design 
Searching for populations with  
large family size 
Selection for extreme traits 
Populations with extreme bottlenecks due  
to historical events 
Designed breeding experiments Selective ascertainment on phenotypes 
Inter-strain variation studies Population/anthropological genetic studies 
Highly inbred species Cultures with inbreeding by design 
 
  
2.6 The Haves and the Have-Nots 
The significance of the genetic contribution to a trait differs for everyone, depend-
ing on the unique genetic architecture and environmental factors affecting an indi-
vidual. Many may smoke, enjoy alcohol excessively and have untreated high blood 
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pressure; still, never develop IA. Their genetic risk is likely very low. Sadly, on the 
other end of the life-style spectrum, some develop IA and even succumb to SAH 
without ever smoking, disliking alcohol and with normotension. They likely have a 
high genetic risk of IA. When aiming to understand the genetic risk of IA, and not 
the genetic background of risk factors such as nicotine addiction, it would be more 
efficient if one would focus on patients that develop IA without having life-style 
related risk factors. Additionally, when trying to improve the grim outcome of IA 
and of SAH, one should give more emphasis to studiing the genetic components to 
the risk of post-SAH cerebral vasospasm (Ducruet et al., 2010). 
 
 
3 The $1000 Genome  
The $1000 genome is a meme that scientists in the field of genetics have long aimed 
for. Sequencing prices have gone down significantly, however, they are still above 
$1000. Currently, whole-exome and whole-genome sequencing prices are around 
$2000-8000, which is low enough to facilitate large-scale sequencing studies and 
projects such as individual tumour sequencing. Furthermore, whole-genome SNP 
genotyping is available from the price-range of $300-500, sold direct-to-consumer. 
 
3.1 Recreational Genetics 
Recreational genetics is based on the concept of direct-to-consumer genotyping. 
This is currently dominated by genome-wide SNP platforms. Results are evaluated 
primarily based on GWAS findings and they calculate an increased or decreased 
risk of common diseases, such as hypertension, compared to the general population, 
or predict phenotypes, such as eye colour. As mentioned before, risk loci identified 
via GWAS predict disease at the individual level weakly, making most of the disease 
predictions by these platforms clinically irrelevant, serving rather as a genetic horo-
scope. Hence the name; recreational genetics. 
 
 
 
4 Preventive Indirect Bypass Surgery in Local Anaes-
thesia: Go-go Bypass 
4.1 Challenges of Current Cerebral Revascularisation Procedures 
Chronic cerebral hypoperfusion due to atherosclerosis or MMD (Scott et al., 2009), 
or the treatment of certain complex aneurysms (Hopkins et al., 1979; Spetzler et al., 
1980; Sanai et al., 2009) may necessitate cerebral revascularisation surgery, to ensure 
vessel perfusion distal to the pathology. Currently, direct bypass surgeries form a 
significant part of cerebral revascularisation procedures. Cerebral bypass surgeries 
are technically challenging, hence confined to a limited number of centres nation-
ally and internationally (Langer et al., 2008; Mesiwala et al., 2008). Factors that 
limit the clinical usefulness of current bypass procedures are their apparent lack of 
efficacy in athero-occlusive diseases (The-EC/IC-Bypass-Study-Group, 1985; Vilela et 
al., 2008; Powers et al., 2011) and the risk of the potentially life-threatening hyper-
perfusion syndrome (Kim et al., 2008). Additionally, general anaesthesia, necessary 
for current bypass surgeries, carries a risk of stroke due to the readily preoperatively 
compromised cerebral blood flow (Kaisti et al., 2003). Therefore, there is an unmet 
clinical need for a technically robust, gradual revascularisation of the brain. Our 
study identified PlGF as a potentially safe and effective angiogenic factor in the 
murine CNS, hence establishing it as a prime candidate for therapeutic cerebral 
angiogenesis.  
 
4.2 PlGF Enhanced Multiple Bur Hole EC-IC Bypass 
I envision a treatment, where indirect multiple bur hole bypass will be enhanced 
with PlGF, thus making indirect revascularisation sufficient in adults. The proce-
dure would consist of the following steps: (1) drilling multiple bur holes over the 
region where revascularisation is desired, (2) careful opening of the dura and arach-
noid membrane followed by the (3) delivery of PlGF expressing AAVs in slow-
releasing biodegradable nanoparticle polymers (Leary et al., 2006), placed into the 
bur holes (Figure 23).  
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Figure 23. Nanoneurosurgery and neurosurgery combined. Schematic image of vascular 
growth factor enhanced EC-IC indirect bypass surgery (modified from (Baaj et 
al., 2009)). 
According to our results, newly formed vessels in mice are already detectable two 
weeks after growth factor treatment. However, AAV mediated gene transfer ensures 
long term expression in the transduced cells and their progeny (Koeberl et al., 
1997). Likely, the haemodynamic needs of the cerebrum would dictate which vessels 
stabilise and which get pruned over time. Both intracerebral injections (Kaplitt et 
al., 2007) and systemic administration of AAV were shown to be free from signifi-
cant side-effects in humans (Nathwani et al., 2011). However, in the case of aiming 
to revascularise a well-defined region, local administration is likely superior to the 
systemic one. Hence we advocate the delivery of AAV locally, adjacent to the brain 
parenchyma.  
 
PlGF enhanced multiple bur hole bypass could be offered as a prophylactic treat-
ment due to its simplicity and consequently low risk rate. Furthermore, it could be 
performed under local anaesthesia and would likely necessitate only a few days of 
perioperative hospitalisation. In the future, PlGF enhanced multiple bur hole indi-
rect EC-IC bypass could possibly be utilised in diseases such as VD, MMD, post-
SAH vasospasm, or during rehabilitation after stroke, since revascularisation of the 
ischaemic brain tissue would likely improve functional outcome (Taguchi et al., 
2004). Looking further into the future, PlGF enhanced indirect EC-IC bypass may 
be combined with techniques such as progenitor cell or stem cell transplantation, in 
order to gain biological and functional restoration of ischaemic brain regions (Moe 
et al., 2005; Farin et al., 2009; Olstorn et al., 2011). The road of translating research 
results into improved patient care is always long, however, these results represent 
important steps in this process. 
 
 
 
 
 
 
 
Zebra (1944) by Victor Vasarely. Reproduced with the kind permission of the Victor Vasarely 
Museum, Pécs, Hungary. 
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Conclusions 
The main findings from the studies presented in this thesis may be summarised as 
follows: based on its genetic background, sporadic IA emerges as an intracranial 
manifestation of a generalised vasculopathy. Furthermore, IA and its traditional risk 
factor, high SBP, share an overlapping genetic background. 
 
The strongest common risk locus to IA is the 9p21 locus (P=1.5x10-22), a well-
studied general cardiovascular risk locus. This, and the lack of a comparably strong 
IA-specific risk locus suggests, that in contrary to prior views, IA does not appear to 
be a disease of its own but rather a part of a generalised vasculopathy prone to in-
tracranial manifestation. Importantly, GWASs were not designed to identify risk 
alleles that are significant at the individual level. The identified loci explain 5.2% of 
the familial risk of developing IA in the Finnish population, hence likely no clini-
cally meaningful genetic screening or cure will be based on them. However, the 
contribution of the common IA risk loci is significant at a population level. By iden-
tifying common IA risk loci and by dissecting the pathomechanisms behind them, 
we gain better understanding of the pathways increasing disease risk, hence possibly 
shaping future public health policies. 
 
Nevertheless, to the best of our current knowledge, the most effective way to lower 
IA and SAH risk at the individual level is treatment of hypertension, smoking cessa-
tion and lowering alcohol consumption to a moderate level. Healthy life-style is the 
best way to get the most out of our genes. 
 
Let it be emphasised once again, that IA formation is an intermediate phenotype 
when aiming to tackle the deadly SAH. Since it is a small, and likely specific sub-
group of IA that ruptures, future studies should focus more on SAH. 
 
Decades of vascular research taught us about angiogenesis and vascular growth fac-
tors and the key elements of therapeutic revascularisation. Translating research 
results into improving the quality of life of patients suffering from cerebral hypoper-
fusion is now ever closer. The results presented here represent the next significant 
step towards therapeutic angiogenesis in the CNS, by identifying PlGF, via system-
atic screening, as the safest, most efficient vascular growth factor in the CNS of a 
model organism. 
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